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Beta cells in pancreatic islets are central to glucose homeostasis. Impaired glucose 
homeostasis resulting in hyperglycemia manifests as type 2 diabetes (T2D).  T2D onset is 
usually preceded by insulin resistance and hyperglycemia, and most patients already have 
dysfunctional beta cells at diagnosis. Intensive glycemic control to reduce chronic 
hyperglycemia delays T2D progression and enhances beta cell preservation, suggesting 
that beta cells are particularly susceptible to chronic high glucose exposure.  However, 
glucotoxicity in beta cells remains poorly understood and limited by a lack of suitable, 
physiologically relevant cell models that are more amenable to molecular manipulation 
than animal models.    
 
The lab has previously derived two clonal and scalable insulin-producing cell lines from 
progenitor cell lines generated from mouse embryos and mouse embryonic stem cells 
(mESCs).   They display the defining characteristics of bona fide beta cells, including 
proper insulin synthesis and storage, glucose-stimulated insulin secretion (GSIS), and 
express genes critical for beta cell function. Herein, I further investigated the biochemical 
and molecular characteristics of these insulin-producing cells by determining if they have 
unique biological pathways that are critical for beta cell survival and function.  To 
identify these pathways in a global unbiased approach, their gene expression profile was 
compared against that of their progenitors. A total of 185 genes were highly expressed in 
the insulin-producing cells, and computational analysis predicted pentose phosphate 
pathway (PPP), clathrin-mediated endocytosis (CME) and peroxisome proliferator-
activated receptor (PPAR) signaling as important pathways in these cells. Notably, these 
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pathways are known to play important roles in beta cells.  Using cell-based assays, I 
observed that mESC-derived insulin-producing ERoSHK cells, like beta cells, 1) relied 
primarily on the PPP for protection against H2O2-mediated oxidative stress; 2) employed 
CME for membrane retrieval and homeostasis following insulin secretion; and 3) 
expressed Ins1 and Ins2 under the regulation of PPARγ. This study demonstrates that the 
dominant biochemical pathways in ERoSHK cells are the same pathways used by beta 
cells to support insulin production and secretion.   
 
Like beta cells, ERoSHK cells were susceptible to glucotoxicity as demonstrated by 
reduced GSIS after six days of high glucose exposure.  To identify the biological 
processes mediating this susceptibility, the gene expression profiles of low and high 
glucose-treated ERoSHK cells were compared. 185 genes were highly expressed in high 
glucose-treated cells and were computationally predicted to alter cell structure and 
survival.  Accordingly, I observed that high glucose treatment 1) increased apoptosis; 2) 
altered colony morphology; 3) depolymerized actin cytoskeleton; and 4) reduced E-
cadherin-mediated cell-cell contact. These changes were coupled with constitutively 
extracellular signal-regulated kinases (ERK) activation. However, constitutive inhibition 
of ERK phosphorylation only partially reversed glucotoxicity-induced changes, i.e. actin 
depolymerization and reduced cell-cell contact, but not increased apoptosis or impaired 
GSIS. This demonstrates that both constitutive activation and inhibition of ERK 
phosphorylation, which are associated with a predominantly depolymerized and 
polymerized actin cytoskeleton respectively, are incompatible with beta cell function and 
survival that both require actin dynamics. Therefore, this study implicates cytoskeleton 
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regulation as central to hyperglycemia-induced beta cell dysfunction and a therapeutic 
target to delay T2D progression.  
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1. CHAPTER ONE: INTRODUCTION 
 
1.1. Glucose homeostasis and pancreatic beta cell physiology 
Glucose is the primary energy source in the body. In healthy individuals, blood glucose 
concentration is tightly regulated by endocrine cells that exist in clusters of three to four 
thousand cells known as islets of Langerhans in the pancreas. Each islet comprises 
multiple cell types, namely beta cells secreting insulin and amylin; alpha cells secreting 
glucagon; delta cells secreting somatostatin; gamma or PP cells secreting pancreatic 
polypeptide and epsilon cells secreting ghrelin. Systemic glucose concentration is mainly 
governed by the regulated release of insulin and glucagon, whose immediate actions are 
to reduce or increase blood glucose respectively. The pancreatic beta cell is the dominant 
cell type that constitutes more than 50% of the islet and is the most broadly studied. It 
secretes insulin in response to glucose and other nutrients, and insulin acts on muscles 
and adipocytes to promote glucose uptake and the liver to inhibit glucose release into the 
blood, reducing postprandial glucose to maintain glucose homeostasis. 
 
The process of glucose-stimulated insulin secretion (GSIS) in beta cells has been 
extensively characterized. Glucose, the principal physiological insulin secretagogue, 
enters the beta cell via the glucose transporter GLUT2. Intracellular glucose is rapidly 
metabolized by glycolysis and in the process increases ATP/ADP ratio. This closes the 
ATP-sensitive SUR1/Kir6.2 potassium channel, and builds up intracellular potassium that 
leads to membrane depolarization. Voltage-gated calcium channels respond by opening 
and facilitating the diffusion of calcium ions into the cell. The increased intracellular 
calcium concentration triggers the fusion of insulin granules with the plasma membrane 
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in a Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor (SNARE)-
dependent process, hence releasing their insulin content (Figure 1).  
 
Figure 1. Sequential events leading from glucose stimulation to insulin secretion in a 
beta cell. Adapted from http://medicinexplained.blogspot.sg/2011/08/insulin-secretion-
local-regulation.html. 
 
Insulin secretion is biphasic consisting of an initial rapid phase from the exocytosis of 
granules that are pre-docked at the plasma membrane, also known as the „readily 
releasable pool‟ of granules; followed by a slower but sustained phase arising from the 
trafficking of granules that reside deeper within the cell to the cell periphery, or the 
„storage-granule pool‟ [1, 2]. This stimulus-secretion coupling is regulated by the 
coordination of the actin cytoskeleton, small GTPases and SNARE proteins [3]. During 
stimulus-secretion, beta cells do not secrete insulin independently of each other but rather 
in a highly synchronized manner. To facilitate such synchrony, they are held tightly 
together in a syncytium by cell adhesion molecules such as cadherins [4] and neural cell 
adhesion molecule (NCAM) [5], and are connected through gap junctions that are 
dependent on E-cadherin-mediated cell adhesion [6]. These gap junctions, formed by an 
assembly of connexin36 (Cx36) molecules, facilitate electrical coupling of beta cells 
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through the exchange of ions and small metabolites [7, 8], and allow for coordinated or 
synchronized insulin release in response to glucose stimulation. 
 
1.2. Diabetes mellitus 
The most common clinical manifestation of impaired glucose homeostasis is diabetes 
mellitus, a group of metabolic disorders characterized by hyperglycemia. It is a fast-
growing epidemic affecting about 347 million people and is predicted to become the 
seventh leading cause of death in the world by 2030 
(http://www.who.int/topics/diabetes_mellitus/en/; accessed April 2013). There are two 
major forms of diabetes. Type 1 (or insulin-dependent or juvenile) diabetes (T1D) is 
characterized by absolute insulin deficiency resulting from the body‟s inability to 
produce insulin. On the other hand, type 2 (or non-insulin-dependent or adult-onset) 
diabetes (T2D) is a disease of relative insulin deficiency due to the body‟s insensitivity to 
insulin actions.  
 
T2D is the prevalent form that affects 90% of all diabetic patients. Unlike T1D that 
results from autoimmune destruction of beta cells, T2D has a less well-defined 
pathogenesis, and is often attributed to a combination of lifestyle factors that include 
obesity and physical inactivity as well as genetic background. Two highly predictive risk  
factors for T2D that also define a prediabetic state are impaired glucose tolerance (IGT) 
and impaired fasting glycemia (IFG) [9]. Based on the diabetes diagnosis criteria defined 
by the World Health Organization (WHO) [10], IGT occurs when plasma glucose is 
higher than 7.8 mM (normal state) but not exceeding 11.1 mM (diabetic state) after a 75 g 
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oral glucose load. IFG is diagnosed when fasting plasma glucose is higher than 6.1 mM 
(normal state) but not exceeding 7.0 mM (diabetic state) (Figure 2). Prediabetes is 
typically asymptomatic and progression to T2D is gradual. As such, clinical 
manifestation of T2D occurs at an advanced stage of the disease with serious 
complications such as cardiovascular disease, foot ulcers and eventual limb amputation, 
diabetic retinopathy, renal failure and diabetic neuropathy, placing a severe economic 
burden on governments and individuals. Such complications also contribute to the three-
fold increased mortality in diabetic patients each year in the US 
(http://www.diabetes.org/diabetes-basics/diabetes-statistics/; accessed April 2013).   
 
Figure 2. WHO diagnostic criteria for prediabetes and diabetes. Impaired fasting 
glucose (IFG) and impaired glucose tolerance (IGT) are conditions of prediabetes. 
Adapted from http://www.pendyffrynmedicalgroup.co.uk/diabetes_protocol.asp. 
 
1.3. Development of type 2 diabetes 
One method to understand the pathogenesis of a slow progressing disease such as T2D is 
through large cohort studies where individuals are profiled before the onset of overt 
diabetes. The development of diabetes had been profiled in a prospective occupational 
cohort study that concluded with 505 incident diabetes cases and 6033 non-diabetic cases 
(British Whitehall II study). In this study, 13-year trajectories of fasting and postload 
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blood glucose, insulin sensitivity and insulin secretion until diabetes diagnosis were 
reported. When compared to non-diabetic cases, incident diabetic cases had higher body-
mass index, fasting and postload plasma glucose, insulin secretion and lower insulin 
sensitivity over the 13-year period. Interestingly, in the final 6 years before T2D 
diagnosis, a rapid rise in fasting and postload glucose was coupled with a steeper 
decrease in insulin sensitivity. More strikingly, a compensatory increase in insulin 
secretion was observed 3-4 years before diagnosis, which decreased steeply ahead of 
diagnosis (Figure 3) [11]. This cohort study highlighted that individuals who developed 
T2D had an overall elevated fasting and postload glucose as early as 13 years before 
diagnosis, although it remained tightly regulated within the normal range until the final 2-
6 years when it accelerated towards a diabetic state. Notably, this glycemic profile was 
associated with a progressive decline in insulin sensitivity that was compensated for by a 
similarly progressive increase in insulin secretion in the initial 7 years of the 13-year 
period, which was followed by exacerbated insulin resistance and beta cell dysfunction in 




Figure 3. Fasting and 2 h postload glucose, insulin sensitivity and beta cell function 
(insulin secretion) trajectories over a period of 13 years before the diagnosis of T2D. 
Data are from the British Whitehall II cohort study of 505 incident diabetes cases. The 
updated homeostasis model assessment (HOMA2) was used to calculate insulin 
sensitivity (HOMA2-%S) and beta cell function (HOMA2-%B) trajectories. Adapted 
from Figure 2 of Tabák et al. [12] with the original study reported in [11]. 
 
T2D ensues from a concurrence of beta cell dysfunction and insulin resistance. One of 
the most radical changes in the field over the past decade has been widespread 
recognition that beta cell function supersedes insulin sensitivity as the critical 
determinant of T2D development [13, 14]. This is evident from genome-wide association 
studies that identified more than 40 genes as risk variants for T2D with a vast majority 
acting through the impairment of insulin secretion rather than insulin action [15-18]. 
Insulin resistance, typically caused by obesity, diet, sedentary lifestyle as well as genetic 
background, has traditionally been regarded as the underlying cause of T2D. Insulin-
responsive tissues include muscle, adipose tissue, liver and brain, with muscles 
accounting for 90% of total body glucose disposal [19]. As insulin resistance develops, 
7 
 
glucose disposal is gradually impaired, resulting in elevated plasma glucose and 
increased metabolic demand for insulin. Beta cells compensate for this partially by 
increasing the rate of insulin secretion through increasing beta cell mass, and this is 
achieved mainly by increasing cell numbers (beta cell hyperplasia) and to some extent by 
increasing cell size (beta cell hypertrophy) [20]. This condition remains asymptomatic 
and can persist for several years, and whether or not individuals develop overt diabetes is 
dependent on the adequacy of beta cell compensation [21], which is in part determined by 
their genetic constitution [14]. Chronically elevated plasma glucose above the 
physiological range imposes a metabolic stress on beta cells and exacerbates beta cell 
dysfunction, eventually culminating in overt T2D when beta cells can no longer 
compensate for the increasing insulin demand. Indeed, data from the United Kingdom 
Prospective Diabetes Study (UKPDS) shows that beta cell function was already reduced 
by about 50% at the time of T2D diagnosis [22, 23].  
 
1.4. Beta cell glucotoxicity 
Prolonged exposure to supraphysiological glucose levels as a consequence of insulin 
resistance is detrimental to certain cell types in the body, a condition termed 
“glucotoxicity”. These include capillary endothelial cells in the retina, mesangial cells in 
the renal glomerulus, and neurons and Schwann cells in peripheral nerves [24], and 
damage to these cell types is responsible for the ensuing diabetic complications. It is now 
evident that pancreatic beta cells are also vulnerable to hyperglycemia. Clinical studies 
have demonstrated that pancreatic beta cell mass and function in T2D patients decline 
progressively with deteriorating glycemic control and increasing duration of diabetes [25-
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27], and this is independent of risk factors and therapeutic interventions (reviewed by 
Wajchenberg [28]).   Conversely, meticulous glycemic control achieved by initiating 
intensive therapy at diabetes diagnosis with either an insulin-based regimen or multiple 
oral hypoglycemic agents preserves beta cell function [29].  Together, these clinical 
evidences suggest that beta cell vulnerability to hyperglycemia toxicity underpins 
diabetes progression. 
 
The impact of hyperglycemia on beta cells progresses from reversible to irreversible and 
is dependent on the duration of exposure [30, 31]. Extended exposure to elevated glucose 
leads first to pancreatic beta cell desensitization – a process characterized by diminished 
first phase insulin response when the „readily releasable pool‟ of granules is depleted. 
This progresses to beta cell exhaustion when the „storage-granule pool‟ becomes 
depleted. Beta cell desensitization and exhaustion are reversible processes as beta cell 
function can be restored by replenishing insulin granules during a rest intervention of 
euglycemia [32, 33]. However, chronic exposure to hyperglycemia causes irreversible 
damage to beta cells as they accumulate defects in insulin production [34-37] and 
eventually undergo apoptosis [38-41], and this extent is classified as glucotoxicity [31, 
42].   
 
Beta cell glucotoxicity has been rigorously investigated over the years and to date it can 
only be described as a complex interplay of several not fully understood mechanisms 
[43]. The vulnerability of pancreatic beta cells and other diabetes-associated cell types to 
glucotoxicity has been attributed to their inability to reduce glucose uptake during 
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hyperglycemia [24].  Excessive glucose uptake has been shown to induce biochemical 
changes such as 1) increased flux through the polyol pathway; 2) enhanced production of 
advanced glycation end products (AGEs); 3) activation of PKC isoforms; and 4) 
increased activity of the hexosamine pathway [24, 43].  The deleterious effects of each of 
these glucotoxic pathways will be described in brief: 1) Excess glucose enters the polyol 
pathway where aldose reductase reduces it to sorbitol and in the process utilizes the 
essential cofactor NADPH. Depletion of NADPH inhibits the synthesis of reduced 
glutathione, an important antioxidant, making the cell susceptible to oxidative stress [44]. 
2) Glucose and other reducing sugars spontaneously glycate intracellular proteins and 
lipids, leading to accumulation of AGEs. AGEs then stimulate reactive oxygen species 
(ROS) production and cause oxidative damage [45].  They also diffuse out of the cell to 
modify proteins in the extracellular matrix [46, 47] or bind to AGE receptors (RAGE). 
Activation of RAGE has been reported to trigger signaling cascades that reduce insulin 
gene transcription and activate NFκB, which leads to reduced insulin production as well 
as chronic inflammation and induction of apoptosis [43, 48]. 3) Hyperglycemia increases 
synthesis of diacylglycerol (DAG), a second messenger and physiological activator of 
PKCs, and this may result in downstream events such as NFκB activation and pro-
inflammatory gene expression, increased levels of NAD(P)H oxidases leading to 
increased ROS, as well as reduced insulin gene expression and GSIS [49, 50]. 4) Excess 
glucose can also be shuttled through the hexosamine pathway. Some of the fructose-6-
phosphate from glycolysis is converted to glucosamine-6-phosphate by the enzyme 
glutamine:fructose-6-phosphate amidotransferase (GFAT). Glucosamine-6-phosphate is 
further metabolized to uridine diphosphate-N-acetylglucosamine (UDPGlcNAc), a 
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substrate of O-GlcNAc modification. O-GlcNAcylation of transcription factors such as 
PDX-1 [51] and FoxO1 [52, 53] may lead to their gain- or loss-of-function, causing gene 
transcription changes that culminate in beta cell defects.  Taken together, these glucotoxic 
pathways have the potential to increase ROS production, modify proteins and lipids that 
result in impairment of beta cell function, promote a pro-inflammatory microenvironment 
and ultimately apoptosis.      
 
1.5. Surrogate for the study of beta cell biology and glucotoxicity  
Since beta cell dysfunction is central to the development and progression of T2D [54], a 
clearer understanding of beta cells and glucotoxicity will facilitate the formulation of 
interventional therapies to preserve beta cell function and viability and ultimately 
improve the prognosis of the disease [55, 56]. However, this has been limited by a lack of 
suitable physiologically relevant models that are amenable to molecular interrogation and 
validation.  As such, I sought to develop an experimental model that enables in-depth 
cellular and molecular studies on beta cell biology and pathogenesis.   
 
The deleterious effects of hyperglycemia on beta cells have been investigated in vivo, ex 
vivo and in vitro. Experimental in vivo rodent models are classified into genetic (or 
spontaneous) and non-genetic (or experimentally-induced) models. Examples of the 
former include the Goto-Kakizaki (GK) and Zucker Diabetic Fatty (ZDF) rat models as 
well as db/db and ob/ob mouse models (reviewed in [57, 58]); and examples of the latter 
include partial pancreatectomy, high fat diet and fructose-fed diet (reviewed in [59]).  
Streptozotocin-induced diabetes is a common non-genetic model in which streptozotocin 
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induces diabetes by destroying beta cells.  This model is thus not suitable for studying 
beta cell glucotoxicity. In vivo models facilitate the study of beta cells in their native 
environment and are ideal for drug validation studies as beta cells are exposed to most of 
the anomalies of T2D such as dyslipidemia, inflammation and cardiovascular 
complications. However, these become confounding factors when the direct effects of 
hyperglycemia on beta cells are being investigated. Other limitations include the high 
cost and limited availability of spontaneous models and long duration of time needed to 
observe hyperglycemia in experimentally-induced models.   
 
The use of primary tissues such as isolated pancreatic islets or pancreatic slices [60] for 
ex vivo studies is advantageous over the use of cell lines as primary islets retain their 
autocrine and paracrine interactions as well as cell-cell contact among the different 
endocrine cells within the three-dimensional cluster, and these interactions play a 
significant role in influencing cell behavior (reviewed in [61]).  Nevertheless, this 
approach is limited by the technical difficulties in maintaining islet function and survival 
in culture, as well as cell type heterogeneity in islet preparations. For example, beta cells 
in isolated pancreatic islets are rapidly lost through apoptosis [62] due to several factors, 
such as hypoxia resulting from the loss of vasculature, as well as loss of cell-matrix 
interactions [63], further limiting the already low yield of islet isolation. Furthermore, 
although beta cells represent the major cell type in pancreatic islets, it is still difficult to 
attribute the data from islet studies directly to beta cells. These challenges represent 




Although animals and tissues have been useful in understanding beta cell biology, they 
are not as amenable to molecular interrogation as cells. In vitro beta cell lines are the 
preferred models for the study of glucotoxicity, as with most studies on the physiology 
and biochemistry of cells. The major advantages of using cell lines is their scalability to 
produce large populations for extensive studies as well as the consistency and 
reproducibility of results obtained from clonal cells. Cell lines also offer various 
experimental possibilities as they are amenable to genetic and pharmacological 
manipulations, aiding the identification of functions of certain genes or signaling 
pathways under various conditions. However, since most cell lines are tumorigenic in 
nature, using them as surrogates may compromise clinical relevance as they may harbor 
abnormal chromosomal content, genetic mutations, aberrant protein expression and 
modified metabolism [64].  
 
Most of the beta cell lines used to date are rodent insulinoma cell lines that were 
generated by Simian virus 40 transformation, overexpression of its T-antigen or 
irradiation. However, common defects in these cell lines include the inability to secrete 
insulin in response to glucose stimulation as well as low insulin content, thus 
compromising their beta cell-like physiology (Table 1). There is a need to establish non-
cancerous beta cell lines, preferably of human origin, as in vitro beta cell surrogates [64]. 
The former has been circumvented using stem cell-derived insulin-producing cell lines. 
Before the commencement of this project, the lab had derived clonal insulin-producing 
cell lines namely ERoSHK, RoSH2.K and MEPI independently from in vitro 
differentiation of mouse embryonic stem cells (mESCs) and mouse embryos. ERoSHK 
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and RoSH2.K were derived from non insulin-producing progenitor cell lines E-RoSH and 
RoSH2 respectively, while MEPI was derived directly from a primary embryo culture 
(Figure 4) [65, 66]. E-RoSH [67] and RoSH2 [68] are lineage-restricted developmental 
intermediates originating from ESCs and embryos respectively, and they express elevated 
mesoderm- and definitive endoderm-associated genes and reduced ectoderm-associated 
genes. As homogeneous cell populations poised for endodermal differentiation, using 
these lineage-restricted progenitors greatly improved the efficiency of deriving insulin-











Figure 4. Schematic representation of the sequential generation of three 
independent clonal insulin-producing cell lines from in vitro differentiation of three 
different but related sources. ERoSHK cells were derived from their E-RoSH 
progenitors that were derived from mESCs; RoSH2.K cells were derived from RoSH 
progenitors that were derived from mouse embryos; while MEPI cells were derived from 
embryos directly. Adapted from Figure 6a of [66]. 
 
Despite being derived from three different cell sources, these insulin-producing lines are 
highly similar in their morphology and functional properties. They also display the 
defining characteristics of bona fide pancreatic beta cells. They synthesize and store 
insulin in typical insulin secretory granules defined by a dense core and clear peripheral 
halo. Immunoelectron microscopy also demonstrated the co-localization of insulin and C-
peptide in these granules and to a lesser density in the Golgi apparatus, indicating proper 
biosynthetic processing of proinsulin and its conversion into insulin. The critical genes 
found in adult mouse beta cells, such as those encoding proinsulin-1 and 2 (Ins1 and 
Ins2), Glut2 (Slc2a2), glucokinase (Gck), prohormone convertases 1/3 (Pcsk1), subunits 
Kir6.2 and SUR1 of ATP-sensitive potassium channels (Kcnj11, Abcc8) and insulin 
16 
 
receptor substrate 2 (Irs2), were expressed in these cells. Plasma membrane-bound Glut2 
and cytosolic glucokinase, two proteins critical for glucose sensing, were also present in 
the cells. Under stimulation by secretagogues such as glucose, tolbutamide and 
glibenclamide, these cells close their ATP-sensitive potassium channels, which leads to 
membrane depolarization, opening of calcium channels and the subsequent release of 
insulin and C-peptide in equimolar ratio – a mechanism resembling that of primary beta 
cells. Most importantly, they can reverse hyperglycemia when grafted into 
streptozotocin-treated mice. These cells also display several properties that make them 
ideal in vitro beta cell surrogates: they are amenable to subcloning from single cells; their 
growth rate and insulin content were stable for up to 9 months of continuous culture; and 
they can withstand repeated cycles of freeze-thaw without loss of cell morphology or 
insulin production [65, 66]. 
 
1.6. Aim and thesis outline 
The overarching aim of this thesis is to identify the molecular pathogenesis of 
glucotoxicity in beta cells.  The pancreatic beta cell is central to glycemic control and loss 
of beta cell function leads to diabetes. T2D is generally initiated by insulin resistance in 
the peripheral tissues that progresses to elevated glycemia. In response, beta cells 
compensate by secreting more insulin to maintain glucose homeostasis. Over time, 
chronically elevated glucose impairs beta cell function and survival and leads to the 




To achieve the over-arching aim, I set two objectives. The first is to assess the beta cell-
like biochemical and molecular characteristics of insulin-producing cell lines and their 
suitability as a surrogate for this study. The second is to demonstrate the vulnerability of 
the cells to high glucose-induced beta cell dysfunction and to use this vulnerability to 
identify glucotoxicity–induced biochemical or molecular aberrations.  
 
The first objective is described in Chapter 2.  In this chapter, I compared the global gene 
expression profiles of ERoSHK, RoSH2.K and MEPI insulin-producing cell lines against 
their non insulin-producing progenitors to reveal biochemical and molecular 
characteristics of the former. The differences in gene expression were extrapolated to 
biological processes and these extrapolations were validated by cell-based assays before 
being assessed for relevance to the function and survival of pancreatic beta cells.  I found 
that the biochemical and molecular characteristics of these insulin-producing cell lines 
are highly similar to bona fide beta cells. In Chapter 3, the highly scalable and clonal 
mESC-derived insulin-producing cell line ERoSHK was treated with high glucose to 
assess their susceptibility to glucotoxicity.  High glucose decreased GSIS and increased 
basal insulin secretion in ERoSHK cells, demonstrating that they resemble pancreatic 
islets in their susceptibility to glucotoxicity and that they were suitable surrogates to 
interrogate the molecular pathology of glucotoxicity in beta cells. An unbiased 
comparative global gene expression profiling between low and high glucose-treated 
ERoSHK cells revealed that high glucose altered gene expression and induced 
constitutive ERK-mediated signal transduction, which led to cytoskeleton changes and 
predisposed the cell towards apoptosis and GSIS impairment. 
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2. CHAPTER TWO: VALIDATION OF EMBRYO- AND EMBRYONIC STEM 
CELL-DERIVED INSULIN-PRODUCING CELL LINES AS SUITABLE 
BETA CELL SURROGATES 
 
2.1. Objective 
To determine if insulin-producing cell lines share biochemical and molecular 
characteristics of beta cells.  
 
2.2. Overview 
In this chapter, I performed an unbiased comparative transcriptome analysis between 
insulin-producing cells and their non insulin-producing progenitor cells.  The RoSH2.K 
and ERoSHK insulin-producing cell lines are highly similar, scalable and clonal, and are 
derived by differentiating two scalable and clonal non insulin-producing progenitor cell 
lines, RoSH2 and E-RoSH respectively.   These attributes enabled the reproducible 
production of large homogeneous cell preparations that are essential for robust 
comparative gene expression studies.    I also used MEPI, an insulin-producing cell line 
that was derived directly from embryo culture. The pentose phosphate pathway (PPP), 
clathrin-mediated endocytosis (CME) and peroxisome proliferator-activated receptor 
(PPAR) signaling pathway were identified to be the major pathways that delineate these 
insulin-producing cells from their progenitors.  Incidentally, these are also pathways that 
are highly important in the function and physiology of pancreatic beta cells.  Based on 
this study, I conclude that the insulin-producing cell lines have acquired the defining 
biochemical and molecular characteristics of beta cells during their differentiation and 
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may serve as suitable beta cell models for downstream glucotoxicity studies. The work 




2.3. Materials and Methods 
2.3.1. Cell culture 
Insulin-producing cells, RoSH2.K, MEPI-1, and ERoSHK-2, -4 and -6 cells as well as the 
progenitor cells, RoSH2 and E-RoSH2, were cultured as described previously [65-67]. 
 
2.3.2. Microarray analysis of gene expression profile  
Total RNA (2 μg) from two biological replicates of RoSH2, RoSH2.K, MEPI-1, E-
RoSH2 and ERoSHK-2, -4 and -6 cells were converted to biotinylated cRNA, amplified 
and purified using the Illumina TotalPrep RNA Amplification Kit (Ambion Inc., Austin, 
TX, USA) according to the manufacturer's directions. Hybridization to the Illumina 
Sentrix MouseRef-8 Expression Beadchip v1.0 and Illumina Sentrix MouseRef-8 
Expression Beadchip v1.1 chips (Illumina Inc., San Diego, CA, USA), washing and 
scanning were performed according to the Illumina BeadStation 500x manual. The 
progenitor cell lines were analyzed using Beadchip v1.0, while the insulin-producing 
cells were analyzed using both Beadchip v1.0 and v1.1. The data were extracted, 
normalized and analyzed using Illumina BeadStudio provided by the manufacturer. 
Transcript signals that were below the limit of detection (LOD) at 99% confidence were 
defined as genes not expressed. Microarray analysis was performed on a GeneSpring GX 
10.0 platform.  Gene datasets specific for each group of cells were uploaded onto 
Ingenuity Pathway Analysis platform (Ingenuity
 
Systems, Mountain View, CA) and 
PANTHER (Protein ANalysis THrough Evolutionary Relationships) Classification 
System [70, 71] for analysis of biological process, molecular functions and pathways. 
2.3.3. Cell treatment  
21 
 
For the study involving H2O2 and dehydroepiandrosterone (DHEA), 20,000 E-RoSH2.1 
or 60,000 ERoSHK-6 cells were plated in each well of a 96-well plate and cultured at 
37°C for 24 h.  Subsequently, the cells were exposed to 0, 200, 400 or 800 μM of H2O2 in 
the presence and absence of 100 μM DHEA for 3 h.  Cell viability was determined by 
trypan blue dye exclusion. E-RoSH2.1 and ERoSHK-6 cells were then exposed to 100 
μM DHEA or 5 μM 6-aminonicotinamide (6-AN) in the absence of H2O2 for 3 h.  Cell 
susceptibility to H2O2 in the presence and absence of DHEA or 6-AN was verified using 
the CytoTox-Fluor Cytotoxicity assay (Promega Corporation, Fitchburg, WI, USA) 
according to the manufacturer‟s protocol. Fluorescence intensity of the cleaved 
fluorogenic peptide substrate bis-AAF-R110 indicating dead cell protease activity was 
measured using the Infinite M200 microplate reader (Tecan Group Ltd, Männedorf, 
Switzerland). Changes in NADH and NADPH levels were assessed by MTT assays. For 
the troglitazone study, 200,000 cells were seeded in each well of a 6-well plate and 
incubated at 37°C for 24 h. Troglitazone was added at final concentrations of 0, 2.5, 5, 10 
or 20 μM for a period of 3 d, after which RNA was extracted from the cells and the 
expression levels of Ins1, Ins2 and Glut2 were quantified by qRT-PCR. For vehicle 
controls, chloroform and DMSO were added in place of DHEA and troglitazone, 
respectively. 
 
2.3.4. MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma-Aldrich, 
St. Louis, MO, USA) was dissolved in sterile phosphate buffered saline (PBS) at a 
concentration of 10 mg/ml and sterile-filtered through a 0.22-μm filter. The MTT 
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solution was stored at 4°C, protected from light. 10 μl of MTT solution and 100 μL of 
culture medium was added to each well of cells in 96-well plates and incubated 
overnight. 100 μl of solubilization buffer from the Cell Quanti-MTT Assay Kit 
(BioAssay Systems, Hayward, CA, USA) was added to each well and the plates were 
incubated at 37°C for 3 h to dissolve the purple formazan. Absorbance at 570 nm was 
measured using a Benchmark Plus Microplate Reader (Bio-Rad Laboratories, Hercules, 
CA, USA). 
 
2.3.5. Transferrin uptake 
Cells were first trypsinized and counted. 1 x 10
6
 cells were washed with PBS twice and 
serum-starved by re-suspending cells in 2 ml of 11.1 mM glucose, serum-free RPMI 
1640 medium for 1 h at 37°C with rotation to remove free transferrin. The medium was 
replaced with either 11.1 or 33.3 mM glucose (high) serum-free RPMI 1640 medium and 
incubated for an additional 45 min. The medium was subsequently replaced with the 
addition of 5 µg/ml Alexa488-conjugated transferrin and incubated for another 30 min. 
Cells were then washed thrice with PBS at room temperature to remove surface and non-
specific labeling, fixed in chilled freshly prepared 1% paraformaldehyde and analyzed 
using flow cytometry.  To assess viability, ERoSHK-6 cells were seeded in 24-well plates 
at 2 x 10
5
 cells per well and incubated at 37°C for 24 h. The culture medium was replaced 
with one containing either 11.1 or 33.3 mM glucose and 0, 7.5, 15 or 30 μM 
chlorpromazine hydrochloride and the cells were incubated for another 24 h. They were 
trypsinized into single cell suspension and the total viable cell number was counted using 
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the Guava ViaCount Assay on a Guava Personal Cell Analysis-96 system (Guava 
Technologies, Hayward, CA, USA). 
 
2.3.6. RT-PCR and qRT-PCR 
Total RNA was extracted using the Nucleospin® RNA/Protein kit (Macherey-Nagel, 
Düren, Germany).  1 μg of total RNA was converted to cDNA using random primers in a 
20 μl reaction volume using a High Capacity cDNA Archive Kit (Applied Biosystems, 
Foster City, CA, USA). For PCR amplification of PPARA, PPARD and PPARG 
transcripts, PCR mixes were prepared using 1 μl of cDNA (20 ng), 1 μl of primer pair (20 
μM) and 18 μl of Platinum PCR Super-mix  (Life Technologies, Carlsbad, CA, USA). 
They were denatured at 92°C for 2 min and subsequently underwent 40 cycles of 92°C 
for 15 s, 58°C for 30 s, and 72°C for 45 s.  PCR reactions were completed with a final 
extension at 72°C for 5 min. The PCR products were then resolved by agarose gel 
electrophoresis.  The primer sequences are listed in Table 2. 
Table 2. Primer sequences for PCR. 
Primer  Sequence (5‟ to 3‟) 
Ppara-fp
a
 CCA CGA AGC CTA CCT GAA GAA 
Ppara-rp
b
 AAT CGG ACC TCT GCC TCT TTG 
Ppard-fp ACT TCA GCA GCC TCT TCC TCA 
Ppard-rp TGT CCT GGA TGG CTT CTA CCT 
Pparg-fp AAG TGC GAT CAA AGT AGA ACC 
Pparg-rp AAA CCT GAT GGC ATT GTG AGA 
Actb-fp TAT CCT GAC CCT GAA GTA CCC 
Actb-rp GGC CAT CTC TTG CTC GAA GTC 
 
 
                                                          
a
 fp denotes forward primer 
b
 rp denotes reverse primer 
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For quantitative PCR, a mixture of 1 μl of cDNA (10 ng), 1 μl of Taqman primer, 8 μl of 
Taqman 2X PCR master mix and 10 μl of distilled water was subjected to amplification 
on an ABI StepOne Plus Real Time PCR system (Applied Biosystems). The cycle 
threshold values obtained were used to calculate the relative transcript levels. Each 
sample was performed in technical and biological triplicates.  The Taqman primer IDs for 
the genes analyzed were Actinb-Mm00607939_s1, Ins1-Mm01259683_g1, Ins2-
Mm00731595_gh, Glut2- Mm00446224_m1, Rbks- Mm00462703_m1, Ncoa1- 
Mm00447958_m1, G6pdx- Mm00656735_g1, Pfkp-Mm00444792_m1, Pik3r3-
Mm00725021_m1, Pdgfa- Mm01205760_m1, Sh3gl2-Mm00490393_m1, Rab5b-
Mm00834147_g1, Sh3kbp1- Mm00451715_m1 (Applied Biosystems). 
 
2.3.7. Statistical analyses 
Statistical significance between 2 samples was determined using unpaired Student‟s t-





2.4.1. Gene expression analysis (performed by co-authors Tian Sheng Chen and Soon 
Sim Tan, Institute of Medical Biology, A*STAR) 
Gene expression profiles of the three groups of cells, namely insulin-producing cell lines 
(ERoSHK, RoSH2.K and MEPI), the progenitor cell lines (mESC-derived E-RoSH cell 
lines and mouse embryo-derived RoSH cell line) and mESCs were prepared by 
hybridization of labeled cRNA to Illumina BeadArray containing about 24,000 unique 
features as described in Section 2.3.2 of Materials and Methods. 
 
Hierarchical clustering of expressed genes in the insulin-producing cell lines revealed 
that as expected, the gene expression profile of the three insulin-producing cell lines 
clustered with one another while that of the progenitor cell lines clustered with one 
another.  Not unexpectedly, the gene expression profile of mESCs was more closely 
related to that of the progenitor cells than to the insulin-producing cells, and the 
progenitor cell lines-derived insulin-producing cell lines ERoSHK and RoSH2.K were 
more closely related to each other than the embryo-derived MEPI cells (Figure 5A).  A 
total of 7888 genes were expressed by the progenitor cells and 2532 genes were 
expressed by the insulin-producing cells.  Of these, 2347 genes were commonly 
expressed at similar levels between both groups, the progenitor cells expressed 5541 
genes at >2-fold higher level and the insulin-producing cells expressed 185 genes at >2-




Figure 5. Gene expression analysis. A) Hierarchical clustering of expressed genes in 
E14 mESCs, E-RoSH and RoSH2 progenitor cells, and ERoSHK, RoSH2.K and MEPI 
insulin-producing cells; B) Distribution profile of expressed genes in insulin-producing 
cells and their progenitor cells as represented by Venn diagram.  5541 genes were highly 
expressed (>2.0 fold) in the progenitor cells, 2347 genes were expressed at similar levels 
in both insulin-producing cells and their progenitor cells, and 185 genes were highly 
expressed (>2.0 fold) in the insulin-producing cells. 
 
The 5541, 2347 and 185 genes were analyzed by PANTHER [70, 71] in which the 
observed frequency of genes for each biological process in each gene set was compared 
with the reference frequency which, in this case, is the frequency of genes for that 
biological process in the National Center for Biotechnology Information (NCBI) 
database.  The analysis disclosed that these 3 sets of genes were over-represented in 64, 
19 and 26 biological processes respectively (Figure 6).  Comparison of these 3 sets 
revealed that 3 biological processes, namely cell structure and motility, monosaccharide 
metabolism and carbohydrate metabolism were present in all 3 sets (Figure 6A).  Another 
3 processes were over-represented in both sets of genes highly expressed by the 
progenitor cells and the insulin-producing cells (Figure 6B), and 16 processes were over-
represented in both the set of genes (Figure 6C) that were highly expressed by the 
progenitor cells and the set of commonly expressed genes.  After removing these 
redundancies, the set of highly expressed genes in the progenitor cells were over-
represented in 42 unique processes while that in the insulin-producing cells were over-
27 
 
represented in 20 unique biological processes (Figure 6D and E).  The 42 unique 
biological processes driven by genes that were highly expressed in the progenitor cells 
were largely involved in cell growth and proliferation such as DNA replication, cell cycle 
control, gene expression, and metabolism (Figure 6D).  On the other hand, the 20 unique 
biological processes driven by genes that were highly expressed by insulin-producing 






Figure 6. PANTHER analysis of expressed genes. The 5541 highly expressed genes in 
the progenitor cells (progenitor cell-specific genes), 2347 similarly expressed genes in 
both insulin-producing cells and their progenitor cells (commonly expressed genes), and 
185 highly expressed genes in the insulin-producing cells (insulin-producing cell-specific 
genes) were analyzed using PANTHER algorithm. Those biological processes whose 
observed frequency exceeds the reference frequency with a P < 0.05 are considered 
significant.  The number of biological processes predicted for each gene set and their 
distribution among the three gene sets are represented by Venn diagram.  The distributed 
biological processes in each segment of the Venn diagram (A to E) and their P values are 
represented graphically. 
 
To identify those biochemical or molecular pathways that are responsible for the unique 
biology of pancreatic β-cells, the 185 genes that were highly expressed in the insulin-
producing cells were analysed by Ingenuity Pathway Analysis (Ingenuity
 
Systems, 
Mountain View, CA).  Eight pathways with a P < 0.05 were identified.  The three most 
significant pathways were the pentose phosphate pathway (PPP), clathrin-mediated 
endocytosis (CME) and peroxisome proliferator-activated receptor (PPAR) signaling 
(Figure 7A).  The expression levels of ten genes randomly selected from genes that were 
classified into these three pathways were further evaluated by qRT-PCR. The ten genes 
were Rbks, G6pd and Pfkp in the PPP; Pik3r3, Sh3kbp1, Pdgfa, Rab5b, Sh3gl2 and Ins2 
in CME; and Pdgfa, Ins2 and Ncoa1 in PPAR signaling. 7 of the 10 genes were up-
regulated by more than two-fold in the insulin-producing ERoSHK-6 cell line as 
compared to its progenitor E-RoSH2.1 cell line (Figure 7B), in concordance with the 





Figure 7. Ingenuity pathway analysis of highly expressed genes in the insulin-
producing cell-specific gene set. A) The 185 highly expressed genes in the insulin-
producing cell-specific gene set were analyzed by Ingenuity Pathway Analysis.  Eight 
pathways with a P < 0.05 were identified.  B) Expression levels of ten genes randomly 
selected from the three most significant pathways in (A).  The genes were Rbks, G6pd, 
Pfkp (pentose phosphate pathway); Pik3r3, Sh3kbp1, Pdgfa, Rab5b, Sh3gl2, Ins2 
(clathrin-mediated endocytosis); and Pdgfa, Ins2, Ncoa1 (PPAR signaling) for both E-
RoSH2 and ERoSHK-6 cells were quantified using qRT-PCR. The relative transcript 
levels of ERoSHK cells normalized to that of E-RoSH cells and represented on a 
logarithmic scale. 7 of the 10 different genes were upregulated in ERoSHK-6 cells. Data 




2.4.2. Pentose phosphate pathway protected ERoSHK but not E-RoSH cells from H2O2-
mediated insult 
PPP is a major metabolic pathway for the metabolism of pentose sugars and the 
generation of NADPH.  NADPH acts mainly as a reducing agent to reduce the coenzyme 
glutathione which in turn converts reactive H2O2 into H2O and prevents conversion of 
H2O2 into cytotoxic hydroxyl free radicals.  As PPP was predicted as the most significant 
pathway based on the 185 genes that were highly expressed in insulin-producing cells, I 
hypothesized that PPP has an important role in their cellular response to H2O2-induced 
oxidative stress. 
 
To elucidate this role, insulin-producing ERoSHK cells and their progenitor E-RoSH 
cells were treated with H2O2 in the absence or presence of dehydroepiandrosterone 
(DHEA), an inhibitor of glucose-6-phosphate dehydrogenase (G6PD) [72], the rate-
limiting enzyme in the PPP.  Exposure of both cell types to increasing concentrations of 
H2O2 to 400 μM caused a corresponding decrease in viability of both cell types (Figure 
8A). However, ERoSHK cells were more resistant to H2O2 toxicity and had a 
significantly higher survival rate at 400 and 800 μM (P = 0.02 and 0.016, respectively).  I 
postulated that PPP mediated this resistance and consistent with this, DHEA abolished 
this resistance such that low H2O2 concentration at 200 μM was highly toxic to ERoSHK 
cells but not E-RoSH cells (Figure 8B).  Exposure to DHEA alone without H2O2 was not 
toxic to either cell type as evidenced by the cell viability assayed by trypan blue dye 
exclusion (Figure 8C) but it significantly reduced the level of MTT activity in ERoSHK 
cells (P < 0.05).  This discrepancy between the two cell viability assays is because the 
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MTT assay measures cell viability by assessing cellular levels of reducing equivalents 
(i.e. NADPH and NADH) [73].  The decreased MTT activity but not trypan blue dye 
exclusion upon DHEA treatment was therefore consistent with the inhibitory effect of 
DHEA on PPP, the major source of NADPH in a cell [74], and a subsequent reduction in 
NADPH level.  The observation that DHEA had little effect on MTT activity in E-RoSH 
cells also suggested that PPP-generated NADPH did not contribute significantly to the 
MTT activity in E-RoSH cells.  To verify that DHEA enhanced the H2O2 cytotoxicity on 
insulin-producing ERoSHK cells through the inhibition of PPP, a second PPP inhibitor, 
6-aminonicotinamide (6-AN) was used.  6-AN is a non-metabolizable analogue of NADP 
and competitive inhibitor of G6PD in the PPP [75]. Like exposure to 100 μM DHEA, 5 
μM 6-AN reduced MTT activity in ERoSHK cells by 39% but not in E-RoSH cells 
(Figure 8D).  However, when the effect of 6-AN and DHEA exposure was assessed by a 
cytotoxic assay that measures the activity of an enzyme released by dying cells, I 
observed that 6-AN and DHEA were only slightly cytotoxic to E-RoSH cells, but not to 
ERoSHK cells (Figure 8E).  These observations were therefore consistent with the above 
observations that PPP inhibitors reduced MTT activity in ERoSHK cells through the 
depletion of NADPH without a deleterious effect on cell viability.  In addition, the 
cytotoxicity of 200 µM H2O2 in ERoSHK cells was also enhanced 4.0 and 2.9 fold (P < 
0.001) by 6-AN or DHEA, respectively. No significant enhancement was observed for E-




Figure 8. Pentose phosphate pathway protected ERoSHK but not E-RoSH cells 
from H2O2-mediated insult. A and B) Effects of hydrogen peroxide without or with 
DHEA treatment.  20,000 E-RoSH or 60,000 ERoSHK cells were plated in each well of a 
96-well plate and cultured for 24 h. They were then either untreated or exposed to 200, 
400 or 800 μM freshly made H2O2 A) in the absence or B) presence of 100 μM DHEA 
for 3 h.  The relative viability was calculated by normalizing the number of viable cells at 
each concentration to that of 0 μM H2O2 as determined by trypan blue dye exclusion.  C) 
Effects of DHEA on cell viability and MTT activity.  ERoSH2 and ERoSHK-6 cells 
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cultured as described in (A, B) were treated with DHEA.  Cell viability was measured by 
trypan blue dye exclusion and the cellular levels of NADH and NADPH were measured 
by MTT assay.  Cell viability and MTT activity were normalized to that of vehicle 
controls.  D) E-RoSH and ERoSHK cells cultured as described in (A, B) were treated 
with 5 μM 6-AN. MTT activity was measured and normalized to vehicle controls.  E) E-
RoSH and ERoSHK cells were treated with DMSO, 5 μM 6-AN and 100 μM DHEA in 
the presence and absence of 200 μM H2O2 for 3 h. Cytotoxicity is represented by the 
increase in fluorescence from cleaved dead cell protease substrate bis-AAF-R110. 
Fluorescence intensities were subtracted from no-cell controls and normalized to vehicle 
controls.  Data are presented as mean ± s.d., n = 3. * P < 0.05; ** P < 0.005. 
 
2.4.3. Clathrin-mediated endocytosis (CME) was glucose-sensitive and critical for the 
survival of insulin-producing ERoSHK cells 
Secretory cells such as insulin-secreting beta cells compensate for excess surface 
membrane that occurs after a stimulated burst of exocytotic activity by retrieving 
membrane by endocytosis [76].  This coupled exocytosis-endocytosis activity is a well 
documented phenomenon in many secretory cell types [77-79].  In insulin-producing 
cells, calcium-dependent CME has been identified as one of the two types of membrane 
retrieval processes [80].  Therefore, I hypothesized that the computationally predicted 
importance of CME in insulin-producing cells was coupled to their main biological 
function of insulin secretion during glucose stimulation.  To assess this importance, the 
rate of transferrin uptake, a classical marker of CME pathway, was measured in both 
ERoSHK cells and their progenitor E-RoSH cells in the presence and absence of glucose 
stimulation.  The lab has previously demonstrated that ERoSHK cells increased insulin 
secretion upon glucose stimulation [65].  When the glucose concentration was increased 
from 11.1 to 33.3 mM, ERoSHK cells exhibited an 89% increase in transferrin 
internalisation (P < 0.001) (Figure 9A).  In contrast, transferrin uptake in E-RoSH cells 
exhibited a much smaller increase of 12% (P < 0.005).  These observations suggest that 
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there was coupling of glucose-stimulated exocytosis of insulin with CME.  Since this 
coupling is important in maintaining membrane homeostasis and therefore cell viability, I 
next postulated that decoupling of CME with glucose-stimulated insulin exocytosis will 
lead to expansion of cell membrane with deleterious consequences.  To test this, 
ERoSHK cells were treated with chlorpromazine, a drug which inhibits CME by 
preventing the formation of clathrin-coated pits on the cell surface [81]. At 7.5 μM and 
15 μM chlorpromazine, ERoSHK cells in 33.3 mM glucose had a significantly reduced 
cell viability relative to cells in 11.1 mM glucose (P < 0.001) (Figure 9B).  
 
Figure 9. Clathrin-mediated endocytosis was glucose-sensitive and critical for the 
survival of insulin-producing ERoSHK cells. A) Cells were trypsinized, washed and 
serum-starved for 1 h before being exposed to 11.1 or 33.3 mM glucose. Alexa488-
conjugated transferrin was added and the cells were subjected to further incubation. They 
were then washed, paraformaldehyde-fixed and analyzed by flow cytometry.  The 
fluorescence of ERoSHK or E-RoSH cells was normalized to that of the respective cell 
type in 11.1 mM glucose.  B) ERoSHK cells were treated with chlorpromazine for 24 h in 
either 11.1 or 33.3 mM glucose.  Cell viability was determined by Guava ViaCount assay 
and relative viability was calculated by normalizing against that of untreated cells.  Data 
are presented as mean ± s.d., n = 3. * P < 0.005; ** P < 0.001. 
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2.4.4. PPARγ activation increased transcription of beta cell-specific genes (performed 
by co-author Soon Sim Tan, Institute of Medical Biology, A*STAR) 
PPAR signaling pathway was predicted as the third most significant pathway over-
represented in the set of genes highly expressed in insulin-producing cells.  PPARs are 
members of a nuclear receptor superfamily that include PPARα, PPARβ(δ) and PPARγ.  
Here, the PPAR signaling pathway could therefore include signaling through any of these 
receptors.  Although transcripts for each of the three receptors were not detected in the 
microarray analysis, they were readily detected in both insulin-producing cells and their 
progenitors by RT-PCR (Figure 10A).  Since PPARγ was reported to up-regulate 
transcription of Pdx1, Ins, Nkx6.1, Glut2 and Gck in pancreatic beta cells [82, 83], I 
postulated that the importance of PPAR signaling in the insulin-producing cells derived 
partly from transcriptional regulation by PPARγ.  To test this hypothesis, ERoSHK and 
E-RoSH cells were treated with troglitazone, a PPARγ agonist and the transcript levels of 
Ins1, Ins2 and Glut2 in the cells before and after treatment were determined by qRT-PCR 
(Figure 10B).   In insulin-producing ERoSHK cells, Ins1 transcript level was significantly 
increased at 5 μM troglitazone while Ins2 transcript level was significantly increased at 
10 μM troglitazone.  However, troglitazone did not have a significant effect on Glut2 
transcript level.  As predicted, troglitazone had no significant effect on the transcript 




Figure 10. PPARγ activation increased transcription of beta cell-specific genes. A) 
20 ng of ERoSHK and E-RoSH cDNA were amplified using primer sets specific for 
PPAR-α, -β and -γ transcripts, respectively. The PCR products were resolved by agarose 
gel electrophoresis.  B) 200,000 cells per well were seeded in a 6-well plate and treated 
with 0, 2.5, 5, 10 and 20 μM troglitazone for 3 d. RNA was extracted from the cells and 
the relative transcript levels of Ins1, Ins2 and Glut2 versus Actb transcript levels were 
determined by qRT-PCR. The relative transcript levels were then normalized against that 






Earlier work from the lab has demonstrated that insulin-producing cells derived from the 
in vitro differentiation of mouse embryos and mESCs can perform the defining functions 
of pancreatic beta cells both in vitro and in vivo, i.e. synthesize and secrete functional 
insulin in response to glucose and maintain glucose homeostasis. Additionally, the lab 
had also previously demonstrated that like freshly isolated mouse islets, these cells 
expressed comparable levels of genes known to be critical for beta cell function. Based 
on these observations, we staked our claim that these cells are suitable surrogates for 
bona fide beta cells. In this study, I aim to further bolster this claim by performing 
genome-wide expression profiling that may reveal biochemical and molecular features in 
these cells that further reflect their beta cell-like physiology. By comparing gene 
expression profiles between insulin-producing cells and their progenitor cells, I have 
identified biological pathways that delineate these insulin-producing cells and these 
pathways are also relevant to beta cell biology. These results suggest that these insulin-
producing cells share biochemical and molecular characteristics of bona fide beta cells.  
 
Using insulin-producing ERoSHK-2, -4 and -6 cell lines, RoSH2.K cell line and MEPI-1 
cell lines that we have previously derived from mESC-derived E-RoSH2.1 cell line, 
embryo-derived RoSH2 cell lines and a primary embryo culture respectively [65, 66], a 
comparative gene expression study using microarray technology was performed. Based 
on genes that were highly expressed by the progenitors, I identified 42 unique biological 
processes that were largely involved in cell growth and proliferation such as DNA 
replication, cell cycle control, gene expression, and metabolism.  This is highly consistent 
with our previously reported observation that the progenitor cells have a much faster 
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population doubling time of 12-15 hours than that of 3-4 days in the insulin-producing 
cells [65-68]. Notably, the 20 unique biological processes over-represented by genes that 
were highly expressed by insulin-producing cells indicated a strong neuronal component.  
Some of these processes include neurogenesis, synaptic transmission, neurotransmitter 
release and neuronal activities.  Such strong similarities between the insulin-secreting 
beta cells of the pancreas and neurons had long been observed and were responsible for 
earlier erroneous postulations that insulin-secreting beta cells have a neuroectodermal 
origin (reviewed [84]).  Notably, the most prominent similarity lies in the most important 
beta cell function, GSIS.  This process is essentially triggered by glucose-sensitive 
membrane depolarization leading to a calcium-dependent exocytosis of secretory 
granules involving SNARE proteins, as described in Section 1.1 of Introduction.  This 
process resembles many aspects of neurotransmitter release where the plasma membrane 
is also depolarized leading to an increased influx of calcium ion through L-type calcium 
ion channels and subsequent exocytosis of secretory granules involving SNARE proteins 
[85].  Beta cells also express many neurotransmitter biosynthetic enzymes such as 
tyrosine hydroxylase, dopa decarboxylase and glutamate decarboxylase, as well as 
neurofilament protein and the neural cell adhesion molecule N-CAM  (reviewed [84]).  
Aside from the neuronal characteristic, the other biological processes are also consistent 
with the unique biology of pancreatic beta cells.  For example, cell communication, 
calcium homeostasis and exocytosis are integral to GSIS.   This exercise demonstrates the 
robustness of the 185 insulin-producing cell-specific genes in delineating the unique beta 
cell-like biology of these cells from their non insulin-producing progenitor cells. 
Therefore, they were further analyzed by Ingenuity to identify biological pathways. 
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Unlike the biological processes predicted using PANTHER, the biological pathways 
predicted by Ingenuity were more amenable to the generation of testable hypotheses 
about the biology of insulin-producing cells.  Three pathways, PPP, CME and PPAR 
signaling were predicted to distinguish the insulin-producing cells from their non insulin-
producing progenitors. 
 
The PPP functions primarily to produce NADPH and pentoses for anabolic activities. The 
extent of its activity in pancreatic beta cells has been a subject of debate over the years 
[86-90]. Nevertheless, it is the major source of NADPH in most cell types, which is a 
reducing equivalent responsible for the reduction of glutathione disulfide (GSSG) to 
glutathione (GSH). One function of GSH is to neutralize toxic oxidants such as lipid 
hydroperoxides and free hydrogen peroxide to their corresponding alcohols or water, 
respectively.  Abnormal glutathione status has been associated with beta cell dysfunction 
and the pathogenesis of long-term complications of diabetes [91], while exposure to 
glutathione significantly reduced oxidative stress and improved beta cell function [92].  
Inhibition of G6PD, a rate limiting enzyme in PPP, has also been shown to cause beta cell 
dysfunction and death [41].  Based on these reports, I postulated that the prominence of 
PPP in the insulin-producing cells relative to their non insulin-producing progenitor cells 
reflected a central role in protecting insulin-producing cells against oxidative stress.  
Consistent with my hypothesis, inhibition of PPP by non-toxic concentrations of G6PD 
inhibitors such as DHEA or 6-AN during H2O2 treatment was highly toxic to the insulin-
producing cells but not to their progenitor cells. I demonstrated here that non-cytotoxic 
concentrations of PPP inhibitors significantly reduced MTT activity of the insulin-
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producing ERoSHK cell line, but not in its progenitor E-RoSH cell line. As the non-
toxicity of the two inhibitors was verified by two different cytotoxic assays, the reduction 
in MTT activity was thus attributed to a reduction in NADPH level as a result of G6PD 
inhibition and not cell viability.  Together, these experimental observations suggest that 
like erythrocytes, insulin-producing cells rely predominantly on the PPP to neutralize 
oxidative stress.  Indeed, a recent study revealed that neonatal rat islets are resistant to 
H2O2 because of a greater use of the PPP to produce NAD(P)H from glucose [93]. 
Interestingly, epidemiological studies of several populations have reported a significant 
direct correlation between G6PD deficiency and risk of diabetes [94-97].  
 
Spégel et al. have also recently identified a role of the PPP in modulating the beta cell 
metabolic response to glucose stimulation and consequently insulin secretion [98]. 
Glucose stimulation led to an 8-fold increase in NADPH/NADP
+
 ratio, which was 
paralleled with a >2.5-fold increase in ribose-5-phosphate (R5P), a precursor required for 
nucleotide synthesis.  Inhibition of PPP with DHEA suppressed R5P and GSH levels as 
well as insulin secretion in INS-1 832/13 cells and rat islets without affecting ATP 
production. This provides yet another evidence of the importance of the PPP in the 
physiological function of pancreatic beta cells.    
 
CME was the second most significant pathway predicted to distinguish the insulin-
producing cells from their progenitors.  For cells such as the insulin-producing cells that 
are actively secreting through fusion of secretory granules with the plasma membrane, 
membrane retrieval is critical in maintaining membrane homeostasis.  Although 
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pancreatic beta cells have been shown to secrete insulin through “kiss and run” 
exocytosis where a fraction of vesicle membrane transiently fused with the plasma 
membrane to release the insulin contents of the vesicles, this form of exocytosis is 
estimated to constitute at most 20% of the exocytotic events [99].  Therefore, most of the 
exocytosis in beta cells occurs through the classical membrane fusion where subsequent 
membrane retrieval is critical in removing excess membrane after exocytosis and in 
maintaining membrane homeostasis [100]. 
 
Pancreatic beta cells are thought to retrieve membrane by two mechanistically different 
endocytotic processes: a fast clathrin-independent endocytosis and a slow clathrin-
dependent endocytosis [80].  Although the relative contributions of these two endocytotic 
processes to membrane retrieval have not been determined, it was observed that 
activation of clathrin-independent endocytosis requires a high concentration of 
cytoplasmic calcium ([Ca
2+
]i) [80].  Since high [Ca
2+
]i can only be maintained transiently 
in cells, it is likely that slow clathrin-dependent endocytosis is the more dominant 
mechanism in membrane retrieval.  Therefore, the prediction that CME delineates the 
insulin-producing cells from their progenitor cells underlined the importance of coupling 
insulin-secretion via exocytosis to CME for membrane retrieval and maintenance of 
membrane homeostasis.  As exposure of ERoSHK cells to high glucose concentration of 
33.3 mM stimulates insulin secretion [65], the observation that high glucose increased 
transferrin uptake in ERoSHK cells much more than that in their progenitor E-RoSH cells 
was consistent with a coupling of insulin exocytosis to CME.  Decoupling of these two 
processes by inhibiting CME with chlorpromazine [81] was more toxic to the insulin-
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producing ERoSHK cells at high glucose concentration when the cells are actively 
secreting insulin.  Together, these observations indicate that CME is vital to the viability 
of insulin-producing cells when they are performing their most critical function: secreting 
insulin in response to high glucose.  Notably, chlorpromazine belongs to a class of 
antipsychotic drugs that has long been associated with T2D and IGT [101]  In animal 
studies, chlorpromazine has been shown to induce significant hyperglycemia in mice 
[102] and attenuate pancreatic beta cell function and mass [103].  This association 
between the use of chlorpromazine and incidence of diabetes, and also its effect on 
glucose regulation, and beta cell function and survival further implicate the importance of 
CME in the biology of insulin-producing cells. 
 
PPAR signaling was also predicted to be very important in insulin-producing cells.  As 
PPAR signaling could include signaling through any member of the PPAR nuclear 
receptor superfamily, and PPARα, PPARβ(δ) and PPARγ were all expressed by both the 
insulin-producing cells and their progenitor cells, I validated this prediction by 
demonstrating that at least one of the receptors was important in the transcription of 
genes highly specific to pancreatic beta cell, i.e. Ins1 and Ins2.  Exposure to troglitazone 
significantly increased Ins1 and Ins2 transcript levels in ERoSHK cells but not their 
progenitor cells.  This observation is consistent with the findings that PPARγ agonists 
increased insulin content in islets and improved GSIS [104, 105]. 
 
In summary of this chapter, we have seen that the transcriptome and consequently the 
biochemical and molecular characteristics of mESC-derived insulin-producing cells have 
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differentiated from those of its progenitor cells to resemble beta cells. These features 
govern their function and survival by reducing their susceptibility to oxidative stress, 
maintaining membrane homeostasis following insulin granule exocytosis, and driving the 
expression of beta cell-specific genes through PPAR activation. This gives us greater 
confidence that the highly scalable and non-cancerous ERoSHK cell line, which exhibits 
a physiology highly similar to beta cells, can qualify as a surrogate for investigating the 




3. CHAPTER THREE: HIGH GLUCOSE PREDISPOSES GENE EXPRESSION 
AND ERK PHOSPHORYLATION TO APOPTOSIS AND IMPAIRED 




To investigate the molecular pathophysiology of chronic high glucose exposure on 
insulin-producing cells by identifying glucotoxicity-induced cellular alterations through 
an unbiased, global comparative gene expression analysis between low and high glucose-
treated ERoSHK cells. 
 
3.2. Overview 
ERoSHK cells are ideal for investigating the effects of chronic hyperglycemia on 
pancreatic beta cells not only for their close resemblance to beta cells but also for their 
capacity to be propagated in culture for extended periods, unlike primary beta cells. 
Being highly scalable, they are therefore amenable to the more efficient high throughput 
analytical tools such as comparative genome- or proteome-wide analysis. Despite 
multiple proposed mechanisms of glucotoxicity on beta cells, they remain poorly 
understood and in some cases, controversial. Here, I attempted to expand the current 
understanding through unbiased comparative gene expression profiling to identify 
cellular changes that are induced by prolonged exposure to high glucose (HG).   
 
ERoSHK cells are routinely cultured in INS medium containing 11.1 mM glucose [65], 
an empirically-determined glucose concentration that promotes optimal survival of rodent 
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islets [106]. To assess the effect of chronic exposure to HG on gene expression, ERoSHK 
cells were exposed to HG (33.3 mM glucose) for 6 days.  This exposure reduced GSIS 
suggesting that the cells were susceptible to glucotoxicity. Analysis of the cellular RNA 
by hybridization to a microarray of gene probes identified 185 genes that are highly up-
regulated in HG-treated ERoSHK cells.  These genes were found to be functionally 
clustered in regulating cell structure and survival.  In concordance with the microarray 
analysis, I observed that HG led to increased apoptosis and changes in ERoSHK colony 
morphology, depolymerization of actin and loss of E-cadherin-mediated cell-cell contact.  
Together, these observations implicated the cytoskeleton as a major target of HG-




3.3. Materials and Methods 
3.3.1. Cell culture 
The ERoSHK6 cell line was used for all experiments in this chapter, and was cultured as 
described in [65].  To investigate the effects of chronic HG exposure as opposed to low 
glucose (LG) exposure, cells were first pre-incubated in INS medium containing 11.1 
mM glucose for 24 h followed by a medium change to one containing either LG (defined 
as 11.1 mM glucose) or HG (defined as 33.3 mM glucose),  The medium was refreshed 
every 2 d. 
 
3.3.2. Insulin secretion assay   
Cells were seeded in 12-well plates at 1 x 10
5 
cells per well and treated with LG or HG 
for 6 d.  They were then washed with Krebs-Ringer bicarbonate buffer with HEPES and 
0.1% BSA (KRBH) [108] and pre-incubated in KRBH containing 2.8 mM glucose for 1 h 
at 37 C.  Cells were then incubated in fresh KRBH containing 2.8 mM glucose for 1 h at 
37°C (basal secretion) followed by KRBH containing 16.7 mM glucose for 1 h at 37°C 
(stimulated secretion).  The incubation buffers were removed and insulin was extracted 
from the attached cells using acid-ethanol.  Insulin in the incubation buffers and cell 
extracts was quantified using the rat/mouse insulin ELISA kit (Millipore, Billerica, MA, 
USA) according to the manufacturer‟s protocol.  Insulin secretion was expressed as a 
percentage of total cellular insulin content, which was the sum of insulin present in the 





3.3.3. Oligonucleotide microarray   
Cells were treated with LG or HG for 6 d.  Total RNA from the samples was extracted 
using the Nucleospin RNA/protein kit (Macherey-Nagel).  500 ng of total RNA from 
each of the biological triplicates of LG or HG-treated cells was reverse transcribed into 
cDNA, amplified to generate biotinylated cRNA and purified using the Illumina 
TotalPrep RNA amplification kit (Ambion Inc.) according to the manufacturer‟s protocol.  
Hybridization to the Illumina MouseRef-8 v2.0 Expression BeadChip (Illumina Inc.), 
washing and scanning were performed according to the Illumina BeadStation 500x 
manual.  Data were extracted and average normalization and background subtraction was 
performed using Illumina BeadStudio Gene Expression Module v3 provided by the 
manufacturer.  Transcript signals below the limit of detection of 95% confidence were 
defined as genes unexpressed, and an expression fold change criteria of 2.0 was used to 
determine up- or down-regulation of genes.  Gene datasets were uploaded onto Ingenuity 
Pathway Analysis platform (Ingenuity Systems) for functional clustering.  
 
Gene expression changes were validated by analyzing expression levels of randomly 
selected genes using quantitative RT-PCR (qRT-PCR).   Briefly, 1 µg of RNA was 
converted to cDNA using random primers in a 20 µl reaction volume using a High 
Capacity cDNA Archive Kit (Applied Biosystems).  A 20 µl qPCR reaction mixture was 
set up to contain 20 ng of cDNA in a 3 µl volume, 250 nM of both forward and reverse 
primers in a 2 µl volume, 5 µl of nuclease-free water and 10 µl of 2X SYBR Green PCR 
Master Mix (Applied Biosystems).  Amplification was performed on ABI StepOne Plus 
Real Time PCR System (Applied Biosystems).  Relative transcript levels were calculated 
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based on comparative changes in cycle threshold values, with Actb as the endogenous 
control.  Primer sequences are listed in Table 3. 
Table 3. Primer sequences for qRT-PCR. 



























                                                          
a
 fp denotes forward primer 
b
 rp denotes reverse primer 
 
3.3.4. Total viable cell count  
Cells were seeded in 24-well plates at 2 x 10
5 
cells per well and treated with LG or HG.  
At each indicated timepoint, triplicate wells in each treatment group were trypsinized into 
single-cells and total viable cell number was counted using the Guava ViaCount assay on 





3.3.5. Cell cycle analysis  
Cells were treated with LG or HG for 6 d and cell cycle analyses were performed at the 
indicated timepoints for a period of 72 h thereafter.  At each timepoint, they were 
harvested by trypsinization into single-cells.  5 x 10
5
 cells were washed and fixed in 70% 
ethanol at -20°C overnight.  They were then collected by centrifugation, resuspended in 
PBS containing 5 µg/ml RNase, DNase-free (Roche Applied Science Inc., Penzberg, 
Upper Bavaria, Germany) and 0.05% Triton X-100 and incubated for 2 h at 37°C with 
rotation.  Subsequently, propidium iodide (Life Technologies) was added to a final 
concentration of 50 µg/ml and DNA content of the cells was measured using the BD 
FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).  Histograms 
were deconvoluted using the ModFit LT v3.2 software (Verity Software House, 
Topsham, ME, USA). 
 
3.3.6. Cell division assay 
Cells were subjected to LG or HG treatment for 6 d, trypsinized into single-cells and 
incubated with 5 µM of carboxyfluorescein diacetate, succinimidyl ester (CFDA-SE, Life 
Technologies) for 15 min at 37°C.  CFDA-SE is a highly cell-permeable, non-fluorescent 
molecule. As it enters a cell, intracellular esterases remove the acetate groups and convert 
it to the highly fluorescent CFSE ester that is retained within cells by its covalent 
attachment to intracellular amines through its succinimidyl group. Intracellular CFSE is 
highly stable and cannot be transferred to adjacent cells. Also due to this stability, the 
fluorescent signal is progressively halved within daughter cells following cell division 




Figure 11. Schematic representation of CFDA-SE fluorescence halving at each cell 
division. n denotes number of cell divisions. 
 
Following CFDA-SE staining, the cells were washed to remove excess dye, resuspended 
in LG or HG INS medium and plated at a density of 1 x 10
6
 cells per well in 6-well 
plates.  Cells were then harvested at the indicated timepoints (0–72 h post CFDA-SE 
staining), fixed in 2% paraformaldehyde and the median fluorescence intensity of the 
cells was measured using the BD FACSCalibur flow cytometer (BD Biosciences).  The 
number of cell divisions (n) at each timepoint was calculated as described in [109].   
Briefly, n = (lg F0/Fn)/lg 2 where F0 is the initial average cellular fluorescence and Fn is 
the average cellular fluorescence at each timepoint.  When time (h) was plotted against n, 
the gradient of the linear graph represents the duration of one cell division (h). 
 
3.3.7. Annexin V assay   
Cells were subjected to LG or HG treatment for 6 d and Annexin V assays were 
performed at the indicated timepoints for a period of 72 h thereafter.  At each timepoint, 
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they were harvested by trypsinization into single-cells. 2 x 10
5
 cells were washed and 
stained using the Annexin V-PE Apoptosis Detection Kit (Merck, KGaA, Darmstadt, 
Germany) according to the manufacturer‟s protocol.  The percentage of Annexin V-
positive cells was quantified on the BD FACSCalibur flow cytometer (BD Biosciences). 
 
3.3.8. Immunocytochemistry   
Cells were seeded onto 20 x 20 mm glass coverslips, subjected to LG or HG treatment for 
6 d, fixed with 4% paraformaldehyde for 15 min and then permeabilized with 0.1% 
Triton X-100 for 3 min.  The cells were then incubated with 4% normal goat serum for 30 
min to block non-specific binding sites, and then incubated with 1:100 diluted purified 
mouse anti-vinculin monoclonal IgG1 clone 7F9 (Millipore) or purified mouse anti-E-
cadherin monoclonal IgG2a clone 36 (BD Biosciences) at 4°C overnight.  Cells were 
subsequently washed and incubated with 1:500 diluted Alexa Fluor 488-conjugated goat 
anti-mouse IgG antibodies (Life Technologies) and 1:500 diluted rhodamine-conjugated 
phalloidin (Millipore) for 1 h.  They were then washed, counterstained with DAPI, 
mounted and visualized using a Zeiss LSM 510 laser scanning confocal microscope (Carl 
Zeiss, Inc., Oberkochen, Germany). 
 
3.3.9. ERK1/2 phosphorylation assay  
Serum starvation was performed by incubating cells in KRBH containing 2.8 mM 
glucose.  Cultured cells were washed with PBS twice and proteins were extracted using 
the Mammalian Cell Extraction Kit (BioVision, Mountain View, CA, USA) 
supplemented with Phosphatase Inhibitor Cocktail 3 (Sigma-Aldrich) according to the 
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manufacturer‟s protocol.  Total protein amount was measured using the Bio-Rad Protein 
Assay (Bio-Rad).  The proteins were electroblotted onto a nitrocellulose membrane after 
first separating on a 4-12% SDS–polyacrylamide gel.  The membrane was blocked with 
StartingBlock T20 (PBS) Blocking Buffer (Thermo Fisher Scientific, Rockford, IL, 
USA) for 30 min at room temperature and incubated with 1:1000 diluted purified rabbit 
anti-phospho-ERK1/2 (Thr202/Tyr204) polyclonal IgG (Cell Signaling Technology, 
Danvers, MA, USA). The blot was then washed and incubated with a horseradish 
peroxidase-conjugated 1:5000 diluted goat anti-rabbit IgG (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA).  The blot was then washed and incubated with HRP-enhanced 
chemiluminescent substrate (Thermo Fisher Scientific) and exposed to an X-ray film.  To 
probe for total ERK1/2, bound antibodies were stripped off the blot by incubating it in 
Restore Western Blot Stripping Buffer (Thermo Fisher Scientific) for 5 min at room 
temperature. A second western blot was performed using 1:1000 diluted purified rabbit 
anti-ERK1/2 polyclonal IgG clone K-23 (Santa Cruz Biotechnology) as primary 
antibodies instead.  Intensities of protein bands were quantified by densitometry using 
ImageJ version 1.44d (NIH, USA). 
 
3.3.10. Statistical analyses   
Statistical significance between two samples was determined using unpaired Student‟s t 





3.4.1. High glucose impaired insulin secretion in ERoSHK cells   
To determine if chronic HG was detrimental to ERoSHK cells, the cells were cultured in 
INS medium containing either LG or HG.  Cells exposed to 6 d of LG or HG treatment 
will hereafter be referred to as ERoSHKLG or ERoSHKHG respectively.  Since HG is 
known to cause beta cell dysfunction, I assessed insulin secretion by ERoSHKLG and 
ERoSHKHG.  Relative to ERoSHKLG, basal insulin secretion of ERoSHKHG when 
assayed in the presence of 2.8 mM glucose increased by 43.70% (P < 0.001) while its 
GSIS as assayed in the presence of 16.7 mM glucose was reduced by 36.33% in 
ERoSHKHG (P < 0.005) (Figure 12). 
 
Figure 12. High glucose impaired insulin secretion in ERoSHK.  Insulin secretion of 
ERoSHKLG and ERoSHKHG in response to 2.8 mM (basal) and 16.7 mM (stimulated) 
glucose, expressed as a percentage of total insulin content.  Data are presented as mean ± 
s.d.; n = 3. *, P < 0.005; **, P < 0.001. 
 
3.4.2. Changes in gene expression of ERoSHKHG cells targeted cell survival and 
structure 
For a better understanding of hyperglycemia-induced cellular changes that result in beta 
cell dysfunction and death, I studied the global gene expression profile of ERoSHKLG and 
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ERoSHKHG by hybridizing labeled cRNA to Illumina BeadArray containing about 
25,700 unique features.  After filtering out genes with detection values below the 
confidence level of 95%, I detected the expression of 6628 genes in ERoSHKLG versus 
6680 genes in ERoSHKHG.  Of these, 6495 genes were expressed at similar levels (<2.0-
fold difference) between the two samples. ERoSHKHG up-regulated the expression of 185 
genes as compared to ERoSHKLG, based on a fold-change cut-off of ≥ 2.0 (Figure 13A).  
These 185 genes highly expressed in ERoSHKHG were analyzed by Ingenuity Pathway 
Analysis (Ingenuity Systems), which clustered the genes based on their cellular functions.  
The 5 most significant cellular functions (P < 0.05) are: 1) cellular assembly and 
organization; 2) cellular growth and proliferation; 3) cell death; 4) cell morphology; and 
5) cell-to-cell signaling and interaction (Figure 13B). To further validate these results 
from microarray analysis, the expression levels of a random sample of 10 genes (two 
from each of these five significant cellular processes) were evaluated by qRT-PCR. The 
10 genes were Actn2 and Tpm2 involved in cellular assembly and organization; Cdkn1a 
and Wnt5a involved in cellular growth and proliferation; Dapk2 and Ppargc1a involved 
in cell death; Mylip and Ninj2 involved in cell morphology; and Cd97 and Ephb3 
involved in cell-to-cell signaling and interaction. Of the ten genes, 8 genes were indeed 
upregulated by more than 2.0-fold in ERoSHKHG as compared to ERoSHKLG, in 




Figure 13. High glucose enhanced the expression of genes that regulate cell survival 
and structure in ERoSHK.  A) Scatter plot was created using Illumina BeadStudio, to 
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display the 6813 genes expressed by both ERoSHKLG and ERoSHKHG and their average 
detection signal on logarithmic scales. Dashed lines represent 2.0-fold difference 
boundaries and grey dots represent the 185 genes up-regulated by ERoSHKHG.  B) The 
185 up-regulated genes were uploaded onto Ingenuity Pathway Analysis, and over-
represented in 23 molecular and cellular functions with P < 0.05 (dashed line). The top 5 
most significant functions are represented by black bars.  C) Expression levels of 10 
randomly selected genes, 2 from each of the top 5 most significant functions, as 
determined by quantitative RT-PCR. Transcript levels are first normalized to Actb 
endogenous control, and then to those of ERoSHKLG. Data are presented as mean ± s.d.; 
n = 3. 
 
 
3.4.3. HG inhibited population growth by increased apoptosis with no significant effect 
on rate of cell division 
Cellular growth and proliferation and cell death were two of the five most significant 
cellular functions that were computationally predicted to be modulated by the HG-
induced changes in gene expression.  Consistent with these predictions, viable cell 
population for ERoSHKLG and ERoSHKHG increased 6.7- and 5.5-fold respectively (P < 
0.001) (Figure 14A).  The first significant difference occurred at day 6.  To ascertain if 
this difference was due to reduced cell division or increased apoptosis, the rate of cell 
division in ERoSHKLG and ERoSHKHG at day 6 and onwards was determined by labeling 
cells with CFDA-SE and monitoring cellular fluorescence over 72 h by flow cytometry. 
Assuming that cellular fluorescence was halved at each cell division, the number of cell 
division over time could be calculated as a function of loss in cellular fluorescence as 
described in Section 3.3.6 of Materials and Methods.  The mean number of cell divisions 
per 24 h over a period of 72 h post-treatment for ERoSHKLG and ERoSHKHG was not 
significantly different at 0.93 versus 0.90 (P > 0.05) (Figure 14B), while the average 
duration of each cell division was 26.12 h versus 25.52 h respectively (Figure 15).  
Therefore the reduced population growth in ERoSHKHG cells was not due to reduced cell 
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division but possibly increased cell death.  Annexin V staining of ERoSHKLG and 
ERoSHKHG cells revealed that apoptosis was consistently higher in ERoSHKHG (Figure 
14C).  Although this increase was small, it was highly significant (P < 0.001).  This was 
further corroborated by cellular DNA content analysis.   Relative to ERoSHKLG,  
ERoSHKHG was arrested in G2/M arrest with less cells in G0/G1 phase (49.77% to 
46.35%, P < 0.005) and S phase (13.20% to 12.22%, P < 0.005) but more in G2/M phase 
(37.03% to 41.44%, P < 0.001).  Consistent with the increased Annexin V-positive 
ERoSHKHG cells, there was also more cellular debris in ERoSHKHG culture as 
represented by the sub-G0 (cell debris) fraction (1.11% to 2.96%, P < 0.001) (Figure 
14D, upper panel).  These differences were maintained over the following 3 d (Figure 
14D, lower panel).  Together, these observations indicated that HG reduced population 
growth of ERoSHK cells by inducing G2/M arrest and increasing apoptosis, without 





Figure 14. HG inhibited population growth by increased apoptosis with no 
significant effect on rate of cell division. A) Cells were cultured in LG or HG 
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conditions and total number of viable cells was quantified each day as determined by 
Guava Viacount assay.  Data are normalized to the number of cells seeded on day 0, and 
represented as mean ± s.d.; n = 3. *, P < 0.001.  B) ERoSHK cells pretreated with LG 
and HG for 6 d were stained with CFDA-SE and the rate of loss of fluorescence signal 
was monitored over 72 h by flow cytometry.  The number of divisions per 24 h during the 
72 h period after 6 d of LG and HG treatment is graphically represented (mean ± s.d.; n = 
3). C) Left panel, ERoSHKLG and ERoSHKHG were stained with phycoerythrin-
conjugated Annexin V and dye fluorescence was measured by flow cytometry.  The gates 
on scatter plots of side-scatter (SSC) versus phycoerythrin fluorescence intensity 
represent Annexin V-positive cells.  Right panel, percentages of Annexin V-positive cells 
were assessed daily over a period of 72 h and graphically represented.  Data are 
presented as mean ± s.d.; n = 3. *, P < 0.001. D) Upper panel, ERoSHKLG and 
ERoSHKHG were fixed, stained with propidium iodide (PI) and dye fluorescence was 
measured by flow cytometry.  Histogram plot of cell number versus PI fluorescence 
intensity was deconvoluted using ModFit LT software.  Percentage of cells in each phase 
of the cell cycle is depicted above their respective peaks. Lower panel, the experiment 
was further repeated 24, 48 and 72 h post treatment and percentages of cells in the 
different cell cycle phases are graphically represented. Data are presented as mean ± 
s.d.; n = 3. *, P < 0.05; **, P < 0.005; ***, P < 0.001. 
 
 
Figure 15. Cell division rate of ERoSHKLG and ERoSHKHG. Duration of cell division 
can be calculated based on the gradient of the best-fit line of the time versus n scatter 
plot, where n is the number of cell divisions at each timepoint (see Section 3.3.6 of 
Materials and Methods). 
 
3.4.4. ERoSHKHG displayed altered cell morphology, disorganized actin cytoskeleton 
and reduced cell-cell adhesion   
The computational prediction that the 185 genes highly expressed in ERoSHKHG were 
involved in cellular assembly and organization, cell morphology and cell-to-cell signaling 
and interaction suggested that ERoSHKHG would be morphologically different from 
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ERoSHKLG.  Furthermore, as execution of these functions would all require modulation 
of the cytoskeleton and cellular adhesion, I speculated that the cytoskeleton and cellular 
adhesion structural changes in ERoSHKHG were also modulated by chronic HG 
treatment.  
 
Consistent with the computational prediction and its attendant implications, ERoSHKHG 
colonies and cells were manifestly different from those of ERoSHKLG which, like the 
MIN6 mouse pancreatic beta cell line [110], grew in tightly packed colonies with close 
cell-cell contact.  In contrast, ERoSHKHG formed smaller colonies of loosely packed cells 
with reduced cell-to-cell contact (Figure 16A).  To assess the role of cytoskeletal 
organization and adhesion molecules in mediating this altered colony morphology, both 
ERoSHKLG and ERoSHKHG were stained with fluorescence-tagged phalloidin and 
antibodies against E-cadherin.  Consistent with the tightly packed cells in ERoSHKLG 
colonies, adjacent cells within each colony shared common boundaries demarcated by E-
cadherin (Figure 16B).   Staining with fluorescence-tagged phalloidin and antibodies 
against vinculin further revealed that the basement actin cytoskeleton in many of the 
ERoSHKLG cells had F-actin stress fibers anchored at focal adhesion sites as indicated by 
vinculin.  In contrast, many ERoSHKHG cells within a colony did not share a common 
boundary with their neighbours and were physically separated by distinctly visible gaps 
between the E-cadherin demarcated membranes, indicating reduced cell-cell adhesion.  
Many of the ERoSHKHG also did not display the focal adhesion-anchored F-actin stress 






Figure 16. High glucose altered cell morphology, disrupted actin organization and 
reduced cell-cell adhesion in ERoSHK.  A) Representative phase contrast images of 
ERoSHKLG and ERoSHKHG showing changes in colony morphology.  Scale bars, 100 
μm.  B) Immunofluorescence staining for E-cadherin (green) in ERoSHKLG and 
ERoSHKHG.   Cells were counterstained with phalloidin (red) for F-actin and DAPI 
(blue) for nuclei.  White arrowheads indicate sites of membrane separation.  Parts of the 
merged image (box with white dashed lines) are magnified in the right panels to clearly 
visualize the co-localization of E-cadherin and cortical actin along the cell periphery, as 
well as gaps between adjacent cells.  Scale bars, 10 μm.  C) Immunofluorescence staining 
for vinculin (green) in ERoSHKLG and ERoSHKHG.   Cells were counterstained with 
phalloidin (red) for F-actin and DAPI (blue) for nuclei.  White arrowheads indicate actin 
stress fibers at the basal membrane.  Scale bars, 10 μm. 
 
3.4.5. Sustained high levels of ERK signaling in ERoSHKHG   
Glucose is known to activate extracellular signal-regulated kinases (ERK) 1/2 in beta 
cells during GSIS [111-113], and ERK1/2 activation has been implicated in actin 
cytoskeletal remodeling [109, 114, 115].  In addition, gene expression analysis revealed 
that a factor reported to be involved in the activation of ERK, TNIP2 (ABIN-2) [116] was 
upregulated by HG.  To determine if ERK signaling played a role in the cytoskeletal 
modifications during chronic HG exposure, P-ERK1/2 levels in ERoSHKLG cells and 
ERoSHKHG were assayed and were found to be comparable (Figure 17A, left panel).  
However, I observed that 2, 4 and 8 h of serum starvation, which expectedly abrogated 
ERK1/2 phosphorylation in ERoSHKLG cells, failed to do so in ERoSHKHG suggesting 
that ERK1/2 phosphorylation was refractory to downregulation by serum starvation and 
possibly to other regulatory controls, and ERoSHKHG cells had constitutively active ERK 
signaling (Figure 17A, right panel).  As a consequence of the relatively high basal P-
ERK1/2 level, glucose stimulation enhanced P-ERK1/2 level by 6.42 ± 2.50-fold in 
ERoSHKLG that were serum-starved for 2 h (P < 0.05).  In serum-starved ERoSHKHG, the 




Figure 17. High glucose induced sustained ERK phosphorylation in ERoSHK.  A) 
Left, relative levels of phosphorylated ERK1/2 total ERK1/2 in ERoSHKLG and 
ERoSHKHG were analyzed by western blotting.  Right, ERoSHKLG and ERoSHKHG were 
pre-incubated in KRBH containing 0.1% BSA for 2, 4 and 8 h before being treated with 
or without a 10 mM glucose stimulation for 10 min.  Relative levels of phosphorylated 
ERK1/2 and total ERK1/2 were then analyzed by western blotting.  B)  3 independent 
ERK phosphorylation assays were performed on ERoSHKLG and ERoSHKHG serum-
starved for 2 h.  The relative intensities of phosphorylated ERK (P-ERK) and total ERK 
protein bands were quantified by densitometry and expressed as a ratio (P-ERK/ERK), 
normalized to that of non-stimulated ERoSHKLG cells.  Data are presented as mean ± 
s.d.; n = 3. *, P < 0.05. 
 
3.4.6. Abrogation of ERK signaling in ERoSHKHG restored colony morphology, actin 
cytoskeletal disruption and loss of cell-cell contact   
The constitutively active P-ERK level in ERoSHKHG and the documented role of P-ERK 
in the regulation of actin cytoskeleton [109, 114, 115] suggested that aberrant ERK 
signaling could be responsible for the disorganized actin cytoskeleton, loss of cell-cell 
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adhesion and changes in colony morphology of ERoSHKHG.  To test this hypothesis, 
ERoSHK cells were cultured in LG or HG in the absence and presence of PD98059, a 
specific pharmacological inhibitor of MEK1/2 which phosphorylates ERK1/2 [117].  To 
optimize the dose concentration of the inhibitor, I tested several inhibitor concentrations 
and determine that the lowest concentration required to reverse morphological changes in 
HG-treated cells was 25 µM.  At this concentration, the inhibitor reduced ERK 
phosphorylation in both ERoSHKLG and ERoSHKHG to the same level (Figure 18A). The 
actin cytoskeleton of PD98059-treated ERoSHKHG cells reverted to that of ERoSHKLG 
cells with stress fibers anchored by focal adhesion sites while PD98059-treated 
ERoSHKLG cells remained phenotypically similar to ERoSHKLG (Figure 18B).  PD98059 
also increased cell-cell contact within ERoSHKHG colonies.  PD98059-treated 
ERoSHKHG cells were tightly packed within each colony and adjacent cells share 
common boundaries delineated by E-cadherin and cortical actin staining by rhodamine-
phalloidin with no visible gaps between cells.  Both PD98059-treated ERoSHKLG and 
ERoSHKHG resembled ERoSHKLG (Figure 19A).  These cytoskeletal changes were also 
consistent with a change in the gross colony morphology of ERoSHKHG to that of 
ERoSHKLG (Figure 19B).  However, the rate of apoptosis in PD98059-treated 
ERoSHKHG was not reduced to that in ERoSHKLG or PD98059-treated ERoSHKLG and 
remained high as in ERoSHKHG (Figure 19C).  I observed that 5 µM PD98059 was 
sufficient to induce significant apoptosis in ERoSHKHG (Figure 20). GSIS was also 
attenuated in both PD98059-treated ERoSHKLG and ERoSHKHG, at levels similar to 






Figure 18. Inhibition of ERK phosphorylation in ERoSHKHG restored actin 
cytoskeleton organization.  A) ERoSHK cells were cultured in LG or HG in the absence 
and presence of 25 µM of PD98059 for 6 d.  Cells were lysed and relative amounts of 
phosphorylated ERK and total ERK were analyzed by western blotting.  Intensities of 
protein bands were quantified by densitometry.  P-ERK/ERK ratios were normalized to 
ERoSHKLG and represented in a column chart. B) Cells were fixed, immunostained for 
vinculin (green) and counterstained with phalloidin (red) for F-actin and DAPI (blue) for 









Figure 19. Inhibition of ERK phosphorylation in ERoSHKHG restored cell-cell 
contact and colony morphology.  A) ERoSHK cells were cultured in LG or HG in the 
absence and presence of 25 µM of PD98059 for 6 d.  Cells were fixed, immunostained 
for E-cadherin (green) and counterstained with phalloidin (red) for F-actin and DAPI 
(blue) for nuclei.  White arrowheads indicate sites of membrane separation.  Parts of the 
merged image (box with white dashed lines) are magnified in the right panels to clearly 
visualize the co-localization of E-cadherin and cortical actin along the cell periphery, as 
well as gaps between adjacent cells.  Scale bars, 10 μm.  B) Representative phase contrast 
images of ERoSHKLG and ERoSHKHG treated with or without PD98059 to show changes 
in colony morphology.  Scale bars, 100 μm.  C) ERoSHKLG and ERoSHKHG treated with 
or without PD98059 were stained with phycoerythrin-conjugated Annexin V and dye 
fluorescence was measured by flow cytometry.  Percentages of Annexin V-positive cells 
are assessed and graphically represented.  Data are presented as mean ± s.d.; n = 3.  D) 
Insulin secretion of ERoSHKLG and ERoSHKHG treated with or without PD98059 in 
response to 2.8 mM (basal) and 16.7 mM (stimulated) glucose, expressed as a percentage 
of total insulin content.  Data are presented as mean ± s.d.; n = 3.  *, P < 0.05; **, P < 





Figure 20. Inhibition of ERK1/2 signaling did not reduce apoptosis in ERoSHKHG.  
ERoSHK cells were treated with LG and HG in combination with various concentrations 
of the ERK1/2 inhibitor PD98059 for 6 d.  The cells were then stained with 
phycoerythrin-conjugated Annexin V and dye fluorescence was measured by flow 
cytometry.  Percentages of Annexin V-positive cells are assessed and graphically 





Metabolic overload of islets from chronic exposure to elevated level of nutrients (e.g. 
glucose) has been postulated to be important in the pathogenesis of T2D [118] and this 
importance is best evidenced by the effectiveness of meticulous glycemic control in  
slowing progression to diabetes and reducing the risk of microvascular and neurological 
complications of diabetes [119].  In insulin-resistant individuals, normoglycemia could be 
maintained with adequate beta cell compensation from increased insulin secretion. When 
this compensation is abrogated by beta cell dysfunction and loss of beta cell mass through 
apoptosis, rapid blood glucose elevation ensues.  This ensuing hyperglycemia causes 
glucotoxicity and beta cell phenotypic alterations to further exacerbate beta cell 
dysfunction and death and leads to poor T2D prognosis [54].    
 
Over the years, multiple mechanistic models for the detrimental effects of hyperglycemia 
on the beta cell have been proposed.  In this study, I analyzed global gene expression 
profiles of LG and HG-treated ERoSHK cells as an unbiased approach to identify HG-
induced cellular aberrations that are candidate mediators of glucotoxicity in pancreatic 
beta cells. As described in Section 1.5, ERoSHK is a clonal mouse embryonic stem cell-
derived line that exhibits the salient functional features of pancreatic beta cells in insulin 
production and secretion.  Unlike primary islets or pancreatic beta cells, ERoSHK cells 
are more amenable to long-term culture without compromising their beta cell-like 
functions and are more suitable for assessing the effects of chronic HG exposure.  As 
demonstrated in this study, these cells also exhibited typical beta cell dysfunction when 
exposed to chronic HG, i.e. impairment of GSIS [22, 36, 37, 120-123].  The impairment 
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of GSIS by chronic hyperglycemia is well documented [reviewed by [124]] in patients 
[125], animals [126, 127], isolated islets [128, 129] and beta cell lines [36, 130, 131].  
After exposure to chronic HG, ERoSHKHG exhibited a substantial increase in basal 
secretion and concomitant reduction in GSIS, consistent with the observations of a 
previous study using rat islets treated with HG for 1 week [129].  In addition, unlike 
others who reported a 20 to 50% apoptosis in pancreatic beta cells within 4-6 d of 
exposure to HG [38, 40, 132], I observed a low but significant increase in apoptosis from 
8.01 to 10.94% only after 6 d of treatment.  This slower and smaller increase in apoptosis 
is more consistent with the slow progressive loss in beta cell mass from apoptosis during 
T2D. 
 
Comparative analysis of the genome-wide expression profiles of ERoSHKLG and 
ERoSHKHG cells revealed that ERoSHKHG cells increased expression of genes 
predominantly involved in modulating cellular functions such as 1) cellular assembly and 
organization; 2) cellular growth and proliferation; 3) cell death; 4) cell morphology; and 
5) cell-to-cell signaling and interaction.  The inclusion of cellular growth and 
proliferation as well as cell death as two of the five most significantly modulated 
processes by glucose-induced genes was consistent with the well documented effects of 
glucotoxicity and validated the use of global gene expression to identify candidate 
cellular functions that are triggered by HG.  Of the remaining three processes, it is 
notable that the common denominator is the involvement of cytoskeleton-mediated 
structure and this was consistent with the structural abnormalities that have been 
observed in isolated islets from T2D cadaveric donors [133].   
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In this study, I observed that morphological changes in cell shape and colony phenotype 
were early definitive manifestations of HG exposure.  Cells within each colony lost their 
tightly packed arrangement.  These changes in colony and cell morphology were 
underpinned by changes in the actin cytoskeleton, focal adhesion and cell-cell interaction 
through E-cadherin.  Unlike ERoSHKLG colonies where adjacent cells within each colony 
shared common boundaries demarcated by E-cadherin, many cells in ERoSHKHG 
colonies were physically separated from each other by distinctly visible gaps between 
plasma membranes.  The gaps between E-cadherin demarcated plasma membranes 
suggested that HG caused disengagement of homotypic E-cadherin interactions.  E-
cadherin is a cell adhesion molecule and homotypic E-cadherin interactions are important 
in the aggregation of beta cells during islet development in mice [4] or MIN6 
pseudoislets.  The observation of disrupted E-cadherin interaction between neighbouring 
ERoSHKHG cells also implicated for the first time the role of hyperglycemia in disrupting 
gap junctional communication not only in T2D vulnerable cell types such as vascular 
smooth muscle, endothelial cells, retinal pericytes and astrocytes [134-140] but also in 
pancreatic islets.  The importance of E-cadherin in maintaining junctional communication 
for beta cell function has been previously demonstrated by a reduction in GSIS upon 
down-regulation of E-cadherin in confluent MIN6B1 cell monolayer [141].  As 
mentioned in Section 1.1 of Introduction, maintaining a tight cell-cell contact of beta 
cells in the islets of Langerhans is important in forming a syncytium to facilitate the 
propagation and synchronization of the stimulus-secretion response through the islet via 
intercellular electrical coupling of membrane depolarization and movement of small 
signal molecules and ions through tight gap junctions [142, 143] that is crucial in 
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mounting a prompt and appropriate first-phase insulin response to nutrient stimuli [144, 
145].  This detrimental effect of hyperglycemia on beta cell connectivity is consistent 
with the well documented “diabetic isletopathy” phenotype in hyperglycemic T2DM 
patients or rodent models of T2DM [146-148]. One of the earliest ultrastructural changes 
in diabetic isletopathy is the loss of adherens junctions and desmosomes, and this loss 
precedes remodeling fibrosis and islet amyloid deposition [149].  Therefore, the reduced 
E-cadherin interaction leading to loss of tight cell-cell junction in ERoSHKHG cells 
represented a mechanism by which GSIS in diabetic patients could be compromised by 
hyperglycemia. 
 
Although the effects of glucose on the modulation of cytoskeleton during insulin 
secretion have been extensively studied, they have been largely limited to transient 
glucose stimulation.  Little is known about the effects of chronic HG on the cytoskeleton 
of insulin-producing cells. By staining with fluorescence-tagged phalloidin and antibody 
against vinculin, I observed that unlike ERoSHKLG cells which had basement F-actin 
stress fibers anchored at vinculin-stained focal adhesion sites, ERoSHKHG cells displayed 
a disorganized actin cytoskeleton that was no longer anchored at focal adhesion sites.  
Cortical actin organization in both ERoSHKLG and ERoSHKHG cells was, however 
morphologically similar.  As dispersed pancreatic beta cells, which exhibit similar 
alterations in actin cytoskeleton, were reported to have constitutive ERK phosphorylation 
[141], I investigated ERK1/2 phosphorylation which is downstream of MAPK signaling 
and has been associated with actin cytoskeleton remodeling, focal adhesion remodeling 
and GSIS [114, 150].  ERoSHKHG cells were found to have constitutively phosphorylated 
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ERK1/2 and this phosphorylation was refractory to serum deprivation.  Inhibition of 
ERK1/2 phosphorylation by PD98059 restored the altered actin cytoskeleton, focal 
adhesions and cell-cell contact in ERoSHKHG cells to resemble that of ERoSHKLG cells.  
These observations suggest that while HG altered gene expression to support cytoskeletal 
modification, HG-induced ERK1/2 phosphorylation was a more proximate regulator of 
the cytoskeleton.  The reversal of glucose-induced cytoskeletal abnormalities by 
PD98059 however did not reverse glucose-induced cell death and impairment of GSIS in 
ERoSHKHG.  Instead, cell death and impaired GSIS were worsened in both ERoSHKHG 
and ERoSHKLG cells.  This PD98059-mediated cell death and GSIS impairment were 
consistent with previous reports of its role in inhibiting CREB phosphorylation leading to 
apoptosis [151] and inhibiting GLP1-potentiation of GSIS [152]. This perplexing failure 
of PD98059 to reverse either cell death or impaired GSIS in ERoSHKHG cells could be 
attributed to the involvement of ERK1/2 phosphorylation in diametrically opposing 
cellular functions.  For example, glucose-induced ERK1/2 phosphorylation has been 
implicated in the long term deleterious effects of HG on the beta cell, namely apoptosis 
and impaired insulin secretory function [39], while adiponectin- or insulin-induced 
ERK1/2 phosphorylation improves cell survival and insulin secretory function [153, 154].  
Therefore, ERK1/2 phosphorylation in the beta cell could be context-dependent, such that 
phosphorylation in one context leads to regulation of the cytoskeleton while in another 
leads to apoptosis and/or GSIS.  As such, a global inhibition of ERK1/2 phosphorylation 
by PD98059 would obscure any context-dependent phosphorylation.  One strategy to 
assess this hypothesis could be to identify the different proteins in the ERK1/2 
interactome and determine if ERK1/2-mediated regulation of the cytoskeleton operates 
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through a different signaling cascade of proteins from that of apoptosis or GSIS.  If so, it 
will also support a corollary of this hypothesis that HG-mediated cytoskeletal regulation 
is decoupled from HG-mediated apoptosis and/or GSIS. However, this would contradict 
the well-established links between the cytoskeleton and GSIS or the cytoskeleton and 
apoptosis.  
 
The critical role of the cytoskeleton in stimulated insulin secretion by pancreatic beta 
cells was recognized in the early 1970s [155, 156]. Insulin exocytosis has been observed 
to occur via at least three different modes of granule fusion with the plasma membrane.  
One mode is fusion of pre-docked granules, the second is the immediate fusion of newly 
recruited granules to the plasma membrane and the third mode is fusion of newly 
recruited granules that were pre-docked [157]. As mentioned in Section 2.5 of Chapter 2, 
insulin exocytosis has also been shown to occur via partial fusion with the plasma 
membrane (termed “kiss-and-run exocytosis”) [85, 158]. Irrespective of the mode of 
granule fusion, the physical execution of GSIS in pancreatic beta cells involves dynamic 
modulation of the cytoskeleton to move secretory vesicles to the inner surface of the 
plasma membrane for docking and exocytotic membrane fusion and fission [159].  As 
such, the cytoskeleton is highly regulated and many components of the cytoskeleton such 
as focal adhesions [115], F-actin [156, 160-164], actin-binding proteins (ABPs) e.g. 
gelsolin, PAK1, N-WASP and cofilin [114, 165, 166] as well as small Rho-family 
GTPases e.g. Rac1 and Cdc42 [3, 108, 167] have been implicated in the regulation of 




To reconcile my hypothesis that HG-mediated cytoskeletal regulation is decoupled from 
HG-mediated apoptosis and/or GSIS with the well-established links between 
cytoskeleton and GSIS or cytoskeleton and apoptosis, we note that actin undergoes both 
depolymerization and polymerization during GSIS. For example, F-actin 
depolymerisation has been shown to enhance GSIS in MIN6 beta cells [114] while 
inhibition of RhoGDI, which activates Cdc42 to promote actin polymerization, also led to 
increased GSIS [168, 169]. These diametrical observations could be reconciled by our 
current molecular understanding of insulin secretion as a multi-phase process that relies 
on active actin remodeling and the alternation of G-actin and F-actin forms between 
phases. The first established role of actin in secretory cells was its barrier function that 
sequesters vesicles and restricts their access to the plasma membrane during a resting 
phase (Figure 21, “1”) [156]. Like many secretory cell types, stimulated secretion 
correlates with transient depolymerization of the actin network [150, 164, 170-172]. This 
helps to mobilize vesicles for access to the plasma membranes (Figure 21, “2”) [173]. 
Following this, actin is assembled into tracks for active vesicle trafficking towards the 
plasma membrane [174, 175] and subsequently disassembled for vesicle docking (Figure 
21, “3”). Thereafter, actin is reassembled for terminal homotypic membrane fusion 
processes in the late post-docking stage of exocytosis (Figure 21, “4”). Finally, following 
exocytosis, actin polymerization/depolymerization dynamics are required for the multiple 
distinct stages of CME (coated pit formation, constriction and internalization) [176], a 





Figure 21. Putative model illustrating the sequential phases of insulin secretion and 
the actin cytoskeleton dynamics required to support this multi-phase process. 
Adapted from Figure 1 of [169].  
 
Therefore, actin dynamics are required to support vesicle mobilization, trafficking, 
docking, fusion and membrane retrieval events during GSIS, and a predilection for either 
a polymerized or depolymerized state would compromise this function.  Incidentally, an 
alternating actin polymerization and depolymerization has also been shown to be 
important in cellular survival [reviewed in  [177]].  This requisite for a dynamic 
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cytoskeleton alternating between polymerized and depolymerized provides a rationale for 
the observations that GSIS and cell survival remained compromised in both ERoSHKHG 
with a depolymerized F-actin cytoskeleton and in PD98059-treated ERoSHKHG with a 
polymerized F-actin cytoskeleton. 
 
In conclusion, this approach of using an unbiased global gene expression analysis to 
uncover candidate beta cell functions affected by chronic HG exposure re-affirmed the 
vulnerability of insulin-secreting cells to glucotoxicity and implicated the role of the 
cytoskeleton in beta cell survival and stimulated insulin secretion.  This study also 
suggested a unifying model linking the cytoskeleton with stimulated insulin secretion and 
beta cell survival.  I propose that HG, through modulation of gene expression and 
ERK1/2 signal transduction, predisposed the actin cytoskeleton in beta cells towards a 
constitutively depolymerized state and compromised the dynamic equilibrium between 
polymerization and depolymerization of the actin cytoskeleton, resulting in defective 
stimulated insulin secretion and decreased beta cell survival.  While inhibition of ERK1/2 
signal transduction by PD98059 reversed the actin cytoskeleton towards a constitutively 
polymerized state, it cannot restore the dynamic equilibrium between polymerization and 
depolymerization of the actin cytoskeleton, and therefore cannot reverse the 
compromised insulin secretion and decreased beta cell survival.
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4. CHAPTER FOUR: CONCLUSIONS 
 
4.1. Empirical findings 
This study was set out to interrogate the molecular pathogenesis of beta cell 
glucotoxicity. I employed a mESC-derived insulin-producing cell line that retains the 
functional characteristics of bona fide beta cells as an in vitro study model. I established 
two objectives: 1) to qualify this insulin-producing cell line as a suitable beta cell 
surrogate by assessing its beta cell-like biochemical and molecular characteristics and 2) 
to demonstrate that this study model, like beta cells, is vulnerable to HG-induced beta cell 
dysfunction and to identify cellular alterations that may contribute to this vulnerability. 
 
The clonal and scalable property of this cell line facilitates the generation of large 
homogeneous cell populations for unbiased omics studies. Comparative genome-wide 
expression profiling using oligonucleotide microarray coupled with functional clustering 
of differentially expressed genes offers a global picture of all cellular activities that differ 
between study groups, and the significance of this analysis can be validated using cell-
based assays. I employed this approach to identify differences between 1) insulin-
producing cell lines and their closely related but non-insulin-producing progenitor cell 
lines to delineate biological pathways unique to the former that may reflect their beta 
cell-like characteristics and 2) LG- and HG-treated cells to highlight cellular alterations 




PPP, CME and PPAR signaling are the 3 most significant pathways that differentiated 
insulin-producing cells from their non insulin-producing progenitors. The identification 
of these pathways has improved our understanding of how insulin-producing cells 
combat oxidative stress, recycle membrane following exocytosis, and regulate the 
expression of genes important for beta cell function. Incidentally, loss of function of 
these pathways in pancreatic beta cells is associated with glucose dysregulation and T2D, 
confirming their importance for beta cell physiology and also highlighting the similarities 
in biochemical and molecular characteristics between these insulin-producing cell lines 
and beta cells.   
 
Consistent with studies using pancreatic islets, I report that HG also caused defective 
insulin secretion and triggered cell death in the ERoSHK insulin-producing cell line, 
justifying the use of this beta cell surrogate for glucotoxicity studies. The gene expression 
of HG-treated cells predisposed them to structural anomalies that manifested as 
morphological changes driven by the loss of E-cadherin-mediated cell-cell adhesion and 
a disorganized cytoskeleton that lacked focal adhesion anchorage. These observations 
were associated with constitutive ERK phosphorylation. Its inhibition by PD98059 
reverted cytoskeletal disorganization and restored E-cadherin interactions, supporting a 
causal relationship between ERK signaling, the actin cytoskeleton and cell-cell contact. 
However, reversing these structural changes restored neither GSIS nor cell viability. 
Based on our current understanding that actin dynamics is a requisite for insulin secretion 
and cell survival, I propose that beta cell glucotoxicity is in part a result of altered gene 
expression and constitutive ERK phosphorylation that stabilizes actin in a predominantly 
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depolymerized state, while constitutive ERK inhibition by a chemical inhibitor stabilizes 
actin in a predominantly polymerized state.  Neither context facilitates actin dynamism 
and thus does not support insulin secretion or cell survival. 
 
4.2. Future perspectives 
The deleterious effects of chronic hyperglycemia have been widely attributed to the 
production of ROS through oxidative phosphorylation of glucose [178]. Reports of low 
levels of antioxidant defenses in beta cells compared to other tissues [179, 180] have led 
to the current popular notion that oxidative stress is a central mechanism underlying the 
pathogenesis of beta cell glucotoxicity. This notion is further supported by numerous 
studies that reported elevated oxidative stress markers in both diabetic patients and rat 
models [181-184], and the reported preservation of beta cell integrity by antioxidants in 
diabetic animal models [185, 186]. Based on these reports, I speculated that after chronic 
HG exposure, ERoSHK cells will be highly vulnerability to exogenous ROS. To my 
surprise, when challenged with exogenous H2O2, ERoSHKHG were more resistant than 
ERoSHKLG, suggesting that HG activated antioxidant defenses in ERoSHK. This 
phenomenon was not observed in H9C2 cardiomyocytes, another cell type that I tested 
(Figure 22A and B). 
 
I attributed this resistance to the predominance of PPP as the major antioxidant defense 
mechanism in insulin-producing cells as demonstrated in Chapter 2. I postulate that 
ERoSHK cells under HG could have shuttled the abundant glucose substrate into the PPP 
to generate more NADPH, enabling the cells to better neutralize exogenous H2O2. 
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Consistent with this, MTT absorbance, which is a measure of the total cellular reducing 
equivalents (i.e. NADH and NADPH), was elevated by 2.5-fold in ERoSHKHG but not in 
HG-cultured H9C2 cardiomyocytes (Figure 22C). This elevated reducing capacity 
provides a molecular rationale for the resilience of ERoSHKHG against exogenous H2O2. 
Interestingly, elevated antioxidant defense was also observed in diabetic islets. Lacraz et 
al. reported that diabetic GK/Par rat islets were more resistant to the deleterious effects of 
ROS-generating agents (H2O2, streptozotocin and alloxan) on insulin secretion than 
normal Wistar rat islets. This elevated antioxidant defense was attributed to 1) up-
regulation of a large set of antioxidant genes that includes superoxide dismutase, catalase, 
glutathione peroxidase-1, thiol/disulfide oxidoreductases, glutaredoxin, thioredoxins, 
thioredoxin reductase and peroxiredoxins; 2) increased abundance of GSH; and notably 
3) increased expression of genes driving NADPH generation, such as G6PD, malic 
enzyme-1 and isocitrate dehydrogenase-1 [187]. Together, these observations suggest 
that pancreatic beta cells could mount an adaptive up-regulation of its antioxidant 
defenses when subjected to chronic hyperglycemia. Although PPP represents the primary 
means by which insulin-producing cells combat oxidative stress, its contribution to this 




Figure 22. High glucose activated antioxidant defenses in ERoSHK cells. A and B) 
ERoSHK and H9C2 cardiomyocytes were cultured under LG or HG for 6 d before being 
treated with or without 200 µM of H2O2 for 3 h. Relative viability (A) and cytotoxicity 
(B) are represented by the increased in fluorescence from cleaved live-cell protease 
substrate GF-AFC and dead-cell protease substrate bis-AAF-R110 respectively 
(MultiTox-Fluor Multiplex Cytotoxicity Assay, Promega). C) Cellular levels of NADH 
and NADPH were measured by MTT assay. Fluorescence intensities and absorbances 
were subtracted from no-cell controls and normalized to LG control.  Data are presented 
as mean ± s.d., n = 3. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
I have also discussed the importance of CME in membrane retrieval following insulin 
secretion. I demonstrated that CME is increased under transient glucose stimulation, and 
its inhibition is lethal to insulin-producing ERoSHK cells under short-term (24 h) HG. As 
mentioned in Section 3.5, actin dynamics are vital for the different stages of CME – 
coated pit formation, constriction and internalization. Therefore, disruption of actin 
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dynamics by chronic HG would have profound ramifications that not only affect multiple 
phases of insulin secretion but also disable CME-mediated membrane homeostasis, 
resulting in beta cell dysfunction and death. This would imply that the loss of actin 
dynamics, rather than oxidative stress, plays a more dominant role in mediating beta cell 
glucotoxicity.  
 
Spatial and temporal regulation of the actin cytoskeleton in response to environmental 
cues is an essential component of many cellular processes such as cell locomotion, 
cytokinesis and vesicle trafficking, malfunctioning of this ability leads to a wide range of 
diseases including cancer, neurological and musculoskeletal disorders [188]. Knowledge 
of the mechanisms controlling actin dynamics is accumulating in recent years. Super-
resolution live-cell imaging systems with high spatial and temporal resolution have 
recently been employed to visualize actin dynamics. In particular, the photo-activation 
localization microscopy (PALM)-based single particle tracking technique has the 
capacity to resolve the directed flow of actin monomers along filaments in a dynamic 
setting [189, 190], and this holds promise to provide new insights on the dynamic 
organization of actin structures in various cellular processes. In addition, ABPs are 
regulators of the actin cytoskeleton that control filament nucleation, elongation, severing, 
capping and depolymerization in response to extracellular signals mediated through Rho-
family GTPases such as RhoA, Rac1 and Cdc42, and the complex structure-function 
relationship between these ABPs and the actin cytoskeleton is beginning to unravel. As 
this study implies that prolonged exposure to HG alone can disrupt actin dynamics to 
impair insulin secretion and trigger beta cell apoptosis, I propose the restoration of actin 
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dynamics to beta cells under chronic hyperglycemia as a novel therapeutic strategy to 
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